[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1557
1. Guay S, Akoum A: Stable inhibition of interleukin 1 receptor type II in Ishikawa cells augments secretion of matrix metalloproteinases: possible role in endometriosis pathophysiology. Reproduction; 2007 Sep;134(3):525-34
MedlinePlus Health Information. consumer health - Endometriosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our previous studies showed a marked deficiency in interleukin 1 receptor type II (IL1R2) in the endometrial tissue of women with endometriosis, particularly in epithelial cells.
  • We believe that such a deficiency in IL1R2, a potent and specific IL1 inhibitor, makes endometrial cells more sensitive to IL1 and less capable of buffering the cytokine's effects, which may lead to functional changes that favor endometriosis development.
  • The main objective of our study was to stably inhibit IL1R2 expression in endometrial cells in order to evaluate the role of IL1R2 deficiency in endometriosis pathophysiology.
  • Stable clones of Ishikawa adenocarcinoma endometrial cells transfected with IL1R2 antisense and showing downregulation of IL1R2 protein expression, or with the empty expression vector alone and showing no noticeable difference in IL1R2 expression, were selected.
  • These in vitro data make plausible a role for IL1R2 deficiency in the capability of endometrial cells to invade the host tissue and develop in ectopic locations.
  • [MeSH-major] Down-Regulation. Endometriosis / etiology. Endometrium / enzymology. Matrix Metalloproteinases / secretion. Receptors, Interleukin-1 Type II / antagonists & inhibitors

  • Genetic Alliance. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17709570.001).
  • [ISSN] 1470-1626
  • [Journal-full-title] Reproduction (Cambridge, England)
  • [ISO-abbreviation] Reproduction
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interleukin-1beta; 0 / Oligonucleotides, Antisense; 0 / Receptors, Interleukin-1 Type I; 0 / Receptors, Interleukin-1 Type II; 0 / Tissue Inhibitor of Metalloproteinase-1; EC 3.4.24.- / Matrix Metalloproteinases; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


2. Monte NM, Webster KA, Neuberg D, Dressler GR, Mutter GL: Joint loss of PAX2 and PTEN expression in endometrial precancers and cancer. Cancer Res; 2010 Aug 1;70(15):6225-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Joint loss of PAX2 and PTEN expression in endometrial precancers and cancer.
  • Latent endometrial carcinoma precancers are normal-appearing endometrial glands with sporadic loss of tumor suppressor gene function such as PTEN.
  • Progression to carcinoma is inefficient and requires additional genetic damage that creates a histologic precursor lesion called endometrial intraepithelial neoplasia (EIN).
  • In this study, we examined loss of PAX2 expression, a gene required for embryonic uterine development, during endometrial carcinogenesis.
  • Normal proliferative, EIN, and malignant (endometrial adenocarcinoma) endometrial tissues were immunostained for PTEN and PAX2.
  • EIN and cancer lesions were scored by the majority pattern.
  • The prevalence of PAX2 protein loss in the sequence of normal to precancer to cancer was 36%, 71%, and 77%, respectively, and for PTEN, it was 49%, 44%, and 68%, respectively.
  • The normal endometrial prevalence of PAX2- or PTEN-deficient latent precancers was unaffected by biopsy indication, but increased significantly with age.
  • Coincident loss of PAX2 and PTEN expression in an individual normal endometrium was seen in 21% of patients, but usually involved different glands.
  • Coincident loss was more common in precancers (31%) and carcinoma (55%), in which case, both markers were protein null in an overlapping clonal distribution.
  • PAX2 and PTEN protein loss occurs independently and accumulates with increasing age in latent precancers of normal premenopausal endometrium.
  • Loss of function of both genes in an overlapping distribution characterizes the clinical emergence of a premalignant lesion which is carried forward to carcinoma.

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Dev Biol. 1999;43(5):463-8 [10535325.001]
  • [Cites] Am J Surg Pathol. 2010 Feb;34(2):137-46 [20061933.001]
  • [Cites] J Natl Cancer Inst. 2000 Jun 7;92(11):924-30 [10841828.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3605-11 [10910075.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4311-4 [11389050.001]
  • [Cites] Am J Pathol. 2001 Jun;158(6):1895-8 [11395362.001]
  • [Cites] Gynecol Oncol. 2001 Nov;83(2):177-85 [11606070.001]
  • [Cites] Oncogene. 2002 Feb 7;21(7):1009-16 [11850818.001]
  • [Cites] Gynecol Oncol. 1991 Apr;41(1):1-16 [2026352.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Feb 15;89(4):1179-83 [1311084.001]
  • [Cites] Am J Obstet Gynecol. 1995 Jan;172(1 Pt 1):227-35 [7847546.001]
  • [Cites] Development. 1995 Dec;121(12):4057-65 [8575306.001]
  • [Cites] Oncogene. 1996 Aug 1;13(3):447-53 [8760285.001]
  • [Cites] Clin Genet. 1999 Jul;56(1):1-9 [10466411.001]
  • [Cites] Cancer Causes Control. 1999 Aug;10(4):277-84 [10482486.001]
  • [Cites] Cancer. 2005 Jun 1;103(11):2304-12 [15856484.001]
  • [Cites] J Am Soc Nephrol. 2005 Sep;16(9):2754-61 [16049068.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5613-7 [16740697.001]
  • [Cites] Int J Gynecol Pathol. 2007 Apr;26(2):103-14 [17413975.001]
  • [Cites] Contraception. 2007 Jun;75(6 Suppl):S60-9 [17531619.001]
  • [Cites] Mod Pathol. 2007 Aug;20(8):856-63 [17529925.001]
  • [Cites] Cancer Res. 2008 Jul 15;68(14):6014-20 [18632658.001]
  • [Cites] Nature. 2008 Dec 4;456(7222):663-6 [19005469.001]
  • [Cites] Int J Cancer. 2008 Dec 15;123(12):2871-9 [18814240.001]
  • [Cites] Cancer. 2009 May 15;115(10):2111-8 [19280590.001]
  • [Cites] Melanoma Res. 2009 Jun;19(3):146-55 [19441164.001]
  • [Cites] Int J Gynecol Pathol. 2009 Nov;28(6):570-8 [19851209.001]
  • [Cites] Hum Mol Genet. 2000 Jan 1;9(1):1-11 [10587573.001]
  • (PMID = 20631067.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA100833-05; United States / NCI NIH HHS / CA / R01 CA100833; United States / NCI NIH HHS / CA / R01 CA100833-05; United States / NCI NIH HHS / CA / R01-CA100833
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / PAX2 Transcription Factor; 0 / PAX2 protein, human; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Other-IDs] NLM/ NIHMS213891; NLM/ PMC2912978
  •  go-up   go-down


3. Florio P, De Falco G, Leucci E, Torricelli M, Torres PB, Toti P, Dell'Anna A, Tiso E, Santopietro R, Leoncini L, Petraglia F: Urocortin expression is downregulated in human endometrial carcinoma. J Endocrinol; 2006 Jul;190(1):99-105
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urocortin expression is downregulated in human endometrial carcinoma.
  • The human endometrium expresses both UCN and CRF, and CRF/UCN receptors type-1 (CRF-R1) and -2 (CRF-R2).
  • CRF-R1 activation inhibits cell growth and proliferation of a tumor cell line derived from the human endometrium, and the UCN signaling pathway has been implicated in tumorigenesis of several tissues.
  • Therefore, we investigated whether UCN mRNA and peptide are expressed by human endometrial adenocarcinoma, and whether their expression changes compared to controls.
  • Samples of well (grade 1; n = 6 endometrioid adenocarcinoma, of whom n = 1 with squamous differentiation, and n = 1 clear-cell carcinoma) and poorly differentiated (grade 3; n = 3 endometrioid adenocarcinoma) endometrial adenocarcinoma were collected from nine women (age range 61-79 years) enrolled at the time of diagnosis.
  • Healthy endometrium was collected from postmenopausal women (controls; n = 13; age range 64-78 years), who underwent hysterectomy for uterine prolapse.
  • UCN mRNA expression was significantly reduced (P < 0.0001) in endometrial adenocarcinoma than in healthy controls.
  • UCN mRNA and peptide expressions are decreased in endometrial adenocarcinoma.
  • These data and the evidence that endometrial cancer expresses UCN receptors and UCN is involved in tumorigenesis of several tissues together suggest a role for UCN in endometrial tumoral cell growth and proliferation.
  • [MeSH-major] Adenocarcinoma / metabolism. Corticotropin-Releasing Hormone / metabolism. Down-Regulation. Endometrial Neoplasms / metabolism
  • [MeSH-minor] Aged. Case-Control Studies. Endometrium / chemistry. Endometrium / metabolism. Female. Humans. Immunohistochemistry / methods. Middle Aged. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Urocortins

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16837614.001).
  • [ISSN] 0022-0795
  • [Journal-full-title] The Journal of endocrinology
  • [ISO-abbreviation] J. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Urocortins; 9015-71-8 / Corticotropin-Releasing Hormone
  •  go-up   go-down


Advertisement
4. Gates EJ, Hirschfield L, Matthews RP, Yap OW: Body mass index as a prognostic factor in endometrioid adenocarcinoma of the endometrium. J Natl Med Assoc; 2006 Nov;98(11):1814-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Body mass index as a prognostic factor in endometrioid adenocarcinoma of the endometrium.
  • OBJECTIVE: To determine if body mass index (BMI) influences tumor expression of HER-2/neu, estrogen and progesterone receptors (ER/PR), and survival in women with endometrial adenocarcinoma.
  • METHODS: Patients diagnosed between January 1992 and December 2001 with endometrioid adenocarcinoma of the uterus were identified.
  • CONCLUSION: In patients with endometrioid adenocarcinoma, low BMI is associated with high stage and tumor expression of HER-2/neu.
  • [MeSH-major] Body Mass Index. Carcinoma, Endometrioid / mortality. Carcinoma, Endometrioid / physiopathology. Endometrial Neoplasms / mortality. Endometrial Neoplasms / physiopathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol. 1979 Sep;54(3):269-77 [471366.001]
  • [Cites] J Natl Cancer Inst. 1977 Oct;59(4):1055-60 [333120.001]
  • [Cites] Cancer Res. 1981 Mar;41(3):1140-7 [6936073.001]
  • [Cites] Gynecol Oncol. 2001 Nov;83(2):388-93 [11606102.001]
  • [Cites] JAMA. 1980 Nov 28;244(21):2419-22 [7431569.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):360-8 [16633364.001]
  • [Cites] Int J Epidemiol. 2006 Feb;35(1):151-8 [16278243.001]
  • [Cites] Am J Epidemiol. 2005 May 15;161(10):939-47 [15870158.001]
  • [Cites] Cancer. 1949 Nov;2(6):964-71, illust [15395195.001]
  • [Cites] Int J Gynecol Pathol. 1999 Apr;18(2):138-43 [10202671.001]
  • [Cites] J Clin Pathol. 1998 Jan;51(1):25-9 [9577367.001]
  • [Cites] Cancer Res. 1997 Nov 15;57(22):5077-85 [9371506.001]
  • [Cites] Gynecol Oncol. 1997 Apr;65(1):138-42 [9103403.001]
  • [Cites] Cancer Lett. 1996 Jan 2;98(2):151-5 [8556702.001]
  • [Cites] Am J Obstet Gynecol. 1995 Dec;173(6):1829-34 [8610771.001]
  • [Cites] Cancer Res. 1995 Dec 1;55(23):5693-8 [7585656.001]
  • [Cites] Nutr Cancer. 1995;23(2):141-9 [7644383.001]
  • [Cites] Am J Obstet Gynecol. 1994 Nov;171(5):1193-8 [7977518.001]
  • [Cites] Cancer Res. 1994 Mar 15;54(6):1604-7 [8137266.001]
  • [Cites] Gynecol Oncol. 1993 Feb;48(2):196-202 [8428691.001]
  • [Cites] Cancer. 1982 Nov 15;50(10):2157-62 [7127255.001]
  • [Cites] Pathol Res Pract. 1982 Aug;174(3):237-56 [7145769.001]
  • [Cites] Gynecol Oncol. 1983 Feb;15(1):10-7 [6822361.001]
  • [Cites] Obstet Gynecol. 1984 Jul;64(1):1-11 [6738931.001]
  • [Cites] Cancer Treat Rep. 1985 Feb;69(2):237-8 [3971394.001]
  • [Cites] Cancer. 1985 Sep 15;56(6):1452-5 [4027879.001]
  • [Cites] Cancer Detect Prev. 1987;10(3-4):237-46 [3568022.001]
  • [Cites] Am J Obstet Gynecol. 1988 Apr;158(4):796-807 [2966586.001]
  • [Cites] Gynecol Oncol. 1990 Sep;38(3):364-6 [2227549.001]
  • [Cites] Rev Fr Gynecol Obstet. 1990 Oct;85(10):513-6 [2263829.001]
  • [Cites] Am J Obstet Gynecol. 1991 Jan;164(1 Pt 1):15-21 [1670908.001]
  • [Cites] Gynecol Oncol. 1992 Nov;47(2):179-85 [1361478.001]
  • (PMID = 17128692.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC2569783
  •  go-up   go-down


5. Wu J, Qian J, Li C, Kwok L, Cheng F, Liu P, Perdomo C, Kotton D, Vaziri C, Anderlind C, Spira A, Cardoso WV, Lü J: miR-129 regulates cell proliferation by downregulating Cdk6 expression. Cell Cycle; 2010 May;9(9):1809-18
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Reduced expression of miR-129 has been reported in multiple tumor cell lines and in primary tumors including medulloblastoma, undifferentiated gastric cancers, lung adenocarcinoma, endometrial cancer and colorectal carcinoma.
  • Here we found that lentiviral-mediated overexpression of miR-129 in mouse lung epithelial cells (E10 cells) results in significant G(1) phase arrest that eventually leads to cell death. miR-129 induce G(1) phase arrest in multiple human lung adenocarcinoma cell lines, suggesting miR-129 targeting of G(1)/S phase-specific regulators.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20404570.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / P01 HL47049; United States / NHLBI NIH HHS / HL / R01HL081800
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / Mirn129 microRNA, human; EC 2.7.11.13 / Protein Kinase C-epsilon; EC 2.7.11.22 / Cyclin-Dependent Kinase 6; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3
  •  go-up   go-down


6. Surazynski A, Jarzabek K, Miltyk W, Wolczynski S, Palka J: Estrogen-dependent regulation of PPAR-gamma signaling on collagen biosynthesis in adenocarcinoma endometrial cells. Neoplasma; 2009;56(5):448-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estrogen-dependent regulation of PPAR-gamma signaling on collagen biosynthesis in adenocarcinoma endometrial cells.
  • The link between estrogen and metabolic developmental factors of endometrial carcinoma is well established.
  • The effect of troglitazone-induced PPAR- gamma activation on estrogen-dependent stimulation of collagen biosynthesis was studied in the Ishikawa endometrial adenocarcinoma cell line.
  • The data document for the first time that inhibitory effect of PPAR- gamma ligands on collagen biosynthesis in endometrial adenocarcinoma cells requires functional estrogen receptor.
  • [MeSH-major] Adenocarcinoma / metabolism. Collagen / biosynthesis. Endometrial Neoplasms / metabolism. Estrogens / pharmacology. PPAR gamma / physiology. Signal Transduction / physiology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19580348.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Chromans; 0 / Estrogens; 0 / PPAR gamma; 0 / Receptors, Estrogen; 0 / Thiazolidinediones; 9007-34-5 / Collagen; I66ZZ0ZN0E / troglitazone
  •  go-up   go-down


7. Mood NI, Eftekhar Z, Haratian A, Saeedi L, Rahimi-Moghaddam P, Yarandi F: A cytohistologic study of atypical glandular cells detected in cervical smears during cervical screening tests in Iran. Int J Gynecol Cancer; 2006 Jan-Feb;16(1):257-61
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among them were cervical intraepithelial neoplasia, basal cell abnormality of undetermined significance, cervical adenocarcinoma, endometrial hyperplasia or adenocarcinoma, vaginal adenocarcinoma, endocervical glandular dysplasia, metastatic breast carcinoma, and simple nonvillous trophoblastic tissue.
  • A majority of these lesions are squamous dysplasia, and a significant number of patients had glandular malignancy.
  • The results of the current study underline the importance of follow-up for patients with the diagnosis of AGC.
  • To our knowledge, this is the first report in Iran showing the significance of AGC diagnosis.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / epidemiology. Cervical Intraepithelial Neoplasia / pathology. Cervix Uteri / pathology. Papanicolaou Test. Uterine Cervical Neoplasms / epidemiology. Uterine Cervical Neoplasms / pathology. Vaginal Smears

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer Screening.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445641.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Moore RG, Brown AK, Miller MC, Badgwell D, Lu Z, Allard WJ, Granai CO, Bast RC Jr, Lu K: Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol; 2008 Aug;110(2):196-201
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus.
  • OBJECTIVE: Tumor markers with increased sensitivity and specificity for endometrial cancer are needed to help monitor response to therapy and to detect recurrent disease.
  • The objectives of this study were to examine the levels of several novel tumor markers HE4, SMRP, CA72.4 and CA125 as potential markers in patients diagnosed with endometrioid adenocarcinoma of the uterus.
  • METHODS: Pre-operative serum samples from surgically staged patients with endometrioid adenocarcinoma of the uterus were analyzed for levels of HE4, SMRP, CA72-4 and CA125.
  • RESULTS: Serum samples from 156 healthy subjects and 171 patients with endometrial cancer (122 stage I, 17 stage II, 26 stage III, and 6 stage IV) were analyzed.
  • At a 95% specificity, the sensitivities for differentiating between healthy subjects and all stages of cancer were 45.5% for HE4 and 24.6% for CA125.
  • CONCLUSION: HE4 is elevated in all stages of endometrial can100cer and is more sensitive in early-stage endometrial cancer compared to CA125.
  • Further investigation of HE4 as a marker for early detection of recurrent endometrial cancer and monitoring response to therapy is warranted.
  • [MeSH-major] Adenocarcinoma / blood. Biomarkers, Tumor / blood. Endometrial Neoplasms / blood. Epididymal Secretory Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Tumor-Associated, Carbohydrate / blood. CA-125 Antigen / blood. Female. GPI-Linked Proteins. Humans. Membrane Glycoproteins / blood. Middle Aged. Neoplasm Staging. Sensitivity and Specificity. beta-Defensins

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2002 Jul;86(1):28-33 [12079296.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Gynecol Oncol. 2003 May;89(2):201-9 [12713981.001]
  • [Cites] Am J Obstet Gynecol. 2003 May;188(5):1195-7 [12748476.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):744-51 [14984936.001]
  • [Cites] J Proteome Res. 2004 May-Jun;3(3):636-43 [15253447.001]
  • [Cites] Am J Obstet Gynecol. 1984 Apr 15;148(8):1057-8 [6201072.001]
  • [Cites] Am J Obstet Gynecol. 1986 Nov;155(5):1097-102 [3465243.001]
  • [Cites] Biometrics. 1988 Sep;44(3):837-45 [3203132.001]
  • [Cites] Gynecol Oncol. 1994 Sep;54(3):292-7 [8088605.001]
  • [Cites] Gynecol Oncol. 1994 Sep;54(3):321-6 [8088608.001]
  • [Cites] Am J Obstet Gynecol. 1996 Apr;174(4):1316-9 [8623863.001]
  • [Cites] Gynecol Oncol. 1997 Jan;64(1):141-6 [8995563.001]
  • [Cites] J Clin Pathol. 1996 Dec;49(12):967-70 [9038731.001]
  • [Cites] Gynecol Oncol. 1997 May;65(2):291-6 [9159340.001]
  • [Cites] Obstet Gynecol. 1997 Sep;90(3):441-7 [9277659.001]
  • [Cites] Cancer Detect Prev. 1999;23(5):397-400 [10468891.001]
  • [Cites] Eur J Gynaecol Oncol. 1999;20(4):315-7 [10475131.001]
  • [Cites] J Reprod Med. 2005 Aug;50(8):585-90 [16220763.001]
  • [Cites] Gynecol Oncol. 2008 Feb;108(2):402-8 [18061248.001]
  • [Cites] Int J Gynecol Cancer. 2002 Jul-Aug;12(4):372-5 [12144685.001]
  • (PMID = 18495222.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA083639; United States / NCI NIH HHS / CA / P50 CA083639; United States / NCI NIH HHS / CA / P50 CA098258; United States / NCI NIH HHS / CA / P50 CA098258
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / CA-72-4 antigen; 0 / DEFB126 protein, human; 0 / Epididymal Secretory Proteins; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / beta-Defensins; 0 / mesothelin
  • [Other-IDs] NLM/ NIHMS243878; NLM/ PMC3594093
  •  go-up   go-down


9. Bigsby GE 4th, Holloway RW, Weppelman B, Reynolds RB, Williams B: Endometroid adenocarcinoma of the uterus with cardiac metastasis. A case report and six-year follow-up. Gynecol Oncol; 2005 Apr;97(1):256-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometroid adenocarcinoma of the uterus with cardiac metastasis. A case report and six-year follow-up.
  • BACKGROUND: There are few reported cases of cardiac metastasis associated with endometrial cancer (EC) and no reports of long-term survival.
  • A total abdominal hysterectomy with pelvic and para-aortic lymhadenectomy was performed with disease confined to the uterus/cervix.
  • At 6.8 years, she died of a constrictive pericarditis with no evidence of disease.
  • [MeSH-major] Adenocarcinoma / secondary. Endometrial Neoplasms / pathology. Heart Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15790471.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Klopp AH, Jhingran A, Ramondetta L, Lu K, Gershenson DM, Eifel PJ: Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation. Gynecol Oncol; 2009 Oct;115(1):6-11
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation.
  • OBJECTIVE: To evaluate treatment outcomes and patterns of recurrence in patients with node-positive (International Federation of Obstetrics and Gynecology stage IIIC) adenocarcinoma of the uterus without serous or clear cell differentiation.
  • METHODS: The records of 71 women who were treated for stage IIIC endometrial adenocarcinoma at our institution between 1984 and 2005 were reviewed.
  • Patients with stage IIIC endometrial adenocarcinoma who underwent surgical staging followed by external beam irradiation had a high rate of cure.
  • Relapses in patients treated with EBRT primarily occurred in patients with grade 3 cancer who may be most likely to benefit from combined-chemoradiation treatment.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Endometrial Neoplasms / radiotherapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19632709.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


11. Ackerman I: Adjuvant pelvic radiation therapy in endometrial cancer: The pro argument. Int J Gynecol Cancer; 2010 Oct;20(11 Suppl 2):S67-9
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant pelvic radiation therapy in endometrial cancer: The pro argument.
  • Adjuvant external beam pelvic radiation therapy for stage I endometrial cancer has become increasingly confusing and controversial.
  • By using evidence from the literature, including the most recent randomized data, an argument is made for the use of external beam pelvic radiotherapy for a 63-year-old woman who has undergone a total abdominal hysterectomy and bilateral salpingo-oophorectomy for a grade 2 endometrioid adenocarcinoma of the uterus with 9 of 12 mm of invasion and the presence of lymphovascular space involvement.
  • [MeSH-major] Carcinoma, Endometrioid / prevention & control. Carcinoma, Endometrioid / radiotherapy. Endometrial Neoplasms / prevention & control. Endometrial Neoplasms / radiotherapy. Neoplasm Recurrence, Local / prevention & control

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21053530.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


12. Espino-Strebel E, Luna JT: Correlation between preoperative serum CA 125 and surgicopathologic prognostic factors in endometrial cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e16524

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between preoperative serum CA 125 and surgicopathologic prognostic factors in endometrial cancer.
  • : e16524 Background: Poor prognostic factors dictating the need for extended surgical staging among endometrial cancer patients can be accurately determined only after laparotomy.
  • This prospective study was conducted to determine the correlation between preoperative serum CA125 and surgicopathologic prognostic factors in endometrial cancer.
  • METHODS: Endometrial cancer patients diagnosed from October 2006 to July 2008 who were eligible for primary surgical treatment were included.
  • RESULTS: Ninety patients with endometrioid endometrial adenocarcinoma were included.
  • It is recommended that serum CA125 determination be part of the preoperative work-up of endometrial cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960797.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Lord SR, Vasudev N, Knight S, Speirs V, Hall G: Prognostic significance of immunohistochemical markers in endometrial cancer treated with chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):e16551

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of immunohistochemical markers in endometrial cancer treated with chemotherapy.
  • : e16551 Background: The proportion of patients receiving chemotherapy for endometrial cancer is increasing both in the adjuvant and advanced setting.
  • The literature describes many prognostic immunohistochemical factors in early stage endometrial cancer, the majority of whom will not receive chemotherapy.
  • The aim of this study was to describe the biomarker expression for endometrial tumours treated with chemotherapy and to assess what constitutes a favourable and unfavourable profile for this patient group.
  • METHODS: For a subset of patients with either endometrioid, serous or a mixed mullerian morphology treated with chemotherapy at our centre between 1996 and 2008 an immunohistochemical profile of 14 biomarkers was studied (ERα, Erβ1, Erβ2, PR, PRB, P53, Rb, E-cad, MDM2, MIB-1, E2F1, p16, p13, and p21).
  • RESULTS: In total 199 patients received chemotherapy for endometrial cancer over the 12 year period studied.
  • The commonest histological subtypes were endometrioid adenocarcinoma (40%), serous carcinoma (24.1%) and mixed mullerian tumours (14.6%).
  • CONCLUSIONS: Positive staining for ERα and PR was of similar frequency to previous studies of early stage endometrial cancer and did not significantly influence prognosis.
  • A greater proportion of patients had serous morphology compared to published series of early stage endometrial cancer.
  • Further study of prognostic factors in larger numbers of patients and built into prospective randomised trials may allow the creation of a prognostic model and guide the development of future clinical trials of targeted therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960814.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Qian J, Weber D, Cochran R, Hossain D, Bostwick DG: Detection of chromosomal anomalies in uterine endometrial carcinoma using fluorescence in situ hybridization (UteroFISH). J Clin Oncol; 2009 May 20;27(15_suppl):5533

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of chromosomal anomalies in uterine endometrial carcinoma using fluorescence in situ hybridization (UteroFISH).
  • : 5533 Background: Endometrial cancer is the most common pelvic gynecological malignancy.
  • The diagnosis of well-differentiated endometrial adenocarcinoma, atypical hyperplasia, and marked hyperplasia is often challenging.
  • We sought to investigate the utility of chromosomal anomalies for the detection of uterine endometrial carcinoma using multitarget fluorescence in situ hybridization (FISH).
  • METHODS: Samples were collected by endometrial brush and processed by liquid-based thin-layer cytological preparation protocol.
  • For study, we collected cytology slides from consecutive cases to include 50 benign, 50 hyperplasia without atypia, 50 atypical hyperplasia, and 50 endometrial cancers.
  • The FISH signals were enumerated in 100 cells per case, and the chromosomal anomalies were correlated with pathologic findings, including histologic diagnoses on endometrial tissue samples.
  • RESULTS: Numeric chromosomal anomalies were found in 0% (0/50) of benign, 20% (10/50) of hyperplasia, 76% of atypical hyperplasia (38/50), and 86% (43/50) of carcinoma specimens.
  • The mean percentage of cells with chromosomal changes was 54% in cancer specimens, significantly higher than that in hyperplasia without atypia (13%, p< 0.0001) and atypical hyperplasia (34%, p< 0.0001).
  • FISH anomalies had an overall sensitivity of 81% and specificity of 90% for the detection of atypical hyperplasia and/or endometrial carcinoma.
  • There was no association with grade of endometrial carcinoma.
  • CONCLUSIONS: Multi-target UteroFISH appeared to be useful for the differential diagnosis of reactive hyperplasia, atypical hyperplasia, and endometrial adenocarcinoma, with a high level of sensitivity and specificity.
  • Endometrial hyperplasia with FISH-detected chromosomal anomalies may require close clinical follow-up.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962491.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Arnaoutakis K, Morse AB, Ambika S, Wong G, Parameswaran R: Practice-based improvement (PBI) via web based tool (WBT) in multidisciplinary gynecologic oncology clinic (MGOC). J Clin Oncol; 2009 May 20;27(15_suppl):e17545

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Few studies document evaluation of risk of late side effects of cancer therapy.
  • Part 1 evaluation showed that 68 % pts had endometrial adenocarcinoma; 20% cervical cancer; 12% uterine sarcoma or carcinosarcoma.
  • No pts had complete fall risk evaluation, estimated dietary calcium (Ca)/vitamin D intake or documented adequacy of Ca or vit D intake.
  • Counseling for appropriate Ca/vitamin D intake was poor (4%/8%).
  • We have targeted areas for improvement for part 2: vit D level evaluation, assessment of and counseling for adequate of Ca/ vit D intake and WBE.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963762.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Goel R, Chen E, Welch S, Laurie S, Siu L, Jonker D, Srinivasan R, Wang L, Ivy P, Oza A, Princess Margaret Hospital Phase II Consortium: Phase I study of E7389/gemcitabine combination in patients with advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e13509

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These two drugs exhibit synergistic cytotoxic effects against the H522 non-small cell lung cancer (NSCLC) xenografts.
  • RESULTS: Patient characteristics: male 11/female 10; median age 59 (range 28-84); performance status 0 /1/2: n=1/13/7; prior chemotherapy 21, prior radiotherapy 7, prior immunotherapy 1; tumour types: ovarian cancer 3, endometrial cancer 3, NSCLC 3, gastric/esophageal adenocarcinoma 3, miscellaneous 9.
  • RESPONSE: partial response 1 (ovarian cancer), stable 8 [minor response 4 (NSCLC 2, endometrial cancer 1, head and neck cancer 1)], progression 8, inevaluable 4.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961270.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Murakami F, Ogawa N, Yamazaki A, Sakurai S, Ishiya T, Katase K, Shimizu Y, Tanada S: Evaluation of preoperative positron emission tomography with computed tomography (PET-CT) for detecting lymph node metastasis in gynecologic carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):5593

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of preoperative positron emission tomography with computed tomography (PET-CT) for detecting lymph node metastasis in gynecologic carcinoma.
  • : 5593 Background: To evaluate the sensitivety, specificity, and accuracy of PET-CT for detecting lymph node metastasis in gynecologic carcinoma.
  • METHODS: Between May 2007 to August 2008, 36 consecutive patients (pts) with cervical carcinoma, endometrial carcinoma and epithelial ovarian carcinoma were enrolled.
  • The sensitivity, specificity and accuracy of preoperative PET-CT to detect LN metastasis were 24%, 99.9%, and 97.5%, respectively.
  • The sensitivity of squamous cell carcinoma (SCC) were 35.7%, that of adenocarcinoma were 8.1%.
  • CONCLUSIONS: The results of our study revealed 76% underdiagnosis (overlooking) in evaluation of preoperative PET-CT in LN metastasis.
  • Using PET-CT for detecting small LN metastasis in gynecologic carcinoma may be unreliable so far.
  • However we found that PLNs are comparatively easy to be detected than PANs, and SCC are comparatively easy to be detected than adenocarcinoma.
  • The improved usability and application of PET-CT for detecting LN metastasis in gynecologic carcinoma have to keep researching constructively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962404.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Bermudez Wagner KM, Thomas MB, Miyamoto C, Micaily B, Hernandez E: Tailored surgical staging and radiation therapy in clinical stage I endometrioid endometrial adenocarcinoma (EEA). J Clin Oncol; 2009 May 20;27(15_suppl):e16511

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tailored surgical staging and radiation therapy in clinical stage I endometrioid endometrial adenocarcinoma (EEA).
  • : e16511 Background: Pelvic lymph node dissection (LND) requirement to adequately stage endometrial cancer has been subject of debate.
  • We conducted an outcome analysis of clinical stage I endometrioid endometrial adenocarcinoma (EEA) patients who underwent surgery with tailored LND and adjuvant therapy (radiation (RT) or chemotherapy) between 1997 and 2008.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960757.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Kumar VJ, Nin CY, Kuei LY, Tan KH, Yeo R, Lam PY: Survival and disease relapse in surgical stage I endometrioid adenocarcinoma of the uterus after adjuvant vaginal vault brachytherapy. Int J Gynecol Cancer; 2010 May;20(4):564-9
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival and disease relapse in surgical stage I endometrioid adenocarcinoma of the uterus after adjuvant vaginal vault brachytherapy.
  • INTRODUCTION: Advanced age, deep myoinvasion, whole cavity or lower uterine segment tumors, poor differentiation, and lymphovascular space invasion are known to increase recurrence risk and adversely affect survival in stage I endometrioid adenocarcinoma of the uterus.
  • METHODS: Data of 162 patients with surgical stage I endometrioid adenocarcinoma of the uterus with an increased risk of recurrence were reviewed from the year 1997 to 2008 at KK Gynaecological Cancer Centre, Singapore.
  • Most patients (54.3%) had surgical stage IC endometrioid adenocarcinoma, whereas the rest had stage IB.
  • Age, lymphovascular space invasion, and tumor volume and location were not significant parameters in surgical stage I endometrioid adenocarcinoma patients who failed.
  • The median survival for recurrent endometrial cancer was 5 years.
  • [MeSH-major] Brachytherapy. Carcinoma, Endometrioid / mortality. Endometrial Neoplasms / mortality. Neoplasm Recurrence, Local / mortality. Radiotherapy, Adjuvant / mortality. Uterine Neoplasms / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20686374.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Cutillo G, Cignini P, Visca P, Vizza E, Sbiroli C: Endometrial biopsy by means of the hysteroscopic resectoscope for the evaluation of tumor differentiation in endometrial cancer: a pilot study. Eur J Surg Oncol; 2007 Sep;33(7):907-10
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial biopsy by means of the hysteroscopic resectoscope for the evaluation of tumor differentiation in endometrial cancer: a pilot study.
  • AIMS: To assess the diagnostic accuracy of endometrial biopsy by means of the hysteroscopic resectoscope (EBHR) in evaluating tumor differentiation in patients with endometrial cancer.
  • METHODS: Between January and December 2005, all the women with a diagnosis of endometrioid adenocarcinoma of the uterus, when admitted to hospital, were enrolled for this study.
  • CONCLUSION: EBHR is a very accurate diagnostic procedure for assessing the preoperative tumor grade in patients with endometrial cancer.
  • [MeSH-major] Endometrial Neoplasms / pathology. Endometrium / pathology. Hysteroscopes. Hysteroscopy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Surg Oncol. 2007 Oct;33(8):1047-8 [17336480.001]
  • (PMID = 17188830.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


21. Montalto SA, Hakmi A, Moth P, Raju KS, Coutts M, Papadopoulos AJ, Devaja O: Well differentiated endometrioid adenocarcinoma of the uterus: a cancer unit or centre case? Eur J Gynaecol Oncol; 2009;30(1):35-9
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Well differentiated endometrioid adenocarcinoma of the uterus: a cancer unit or centre case?
  • OBJECTIVE: The purpose of this study was to investigate what proportion of cases showing a well differentiated endometrioid endometrial adenocarcinoma in the hysterectomy specimen removed at two UK cancer centres had adverse pathological features or advanced stage disease at the time of presentation.
  • STUDY DESIGN: Ninety-eight patients who were operated on at either the South East London Cancer Centre, London or the Kent Oncology Centre, Maidstone had a histological diagnosis of well differentiated (grade 1) endometrioid adenocarcinoma in their hysterectomy specimen.
  • RESULTS: Of the initial 98 cases, 65 patients (66.3%) were referred with a preoperative curettage showing a well differentiated endometrioid adenocarcinoma, 25 cases (25.5%) were referred with atypical endometrial hyperplasia, seven patients (7.1%) were referred with a moderately differentiated endometrioid adenocarcinoma, and one case (1.0%) was referred with a possible malignant mixed Mullerian tumour.
  • Subsequent histological examination of the hysterectomy specimens revealed that all of these cases had a well differentiated endometrioid adenocarcinoma.
  • From our study, 33.6% of cases with a well differentiated endometrioid adenocarcinoma of the uterus were Stage Ic or more at the time of presentation; 12.2% were at least FIGO Stage Ic, eight patients (8.2%) were FIGO Stage IIa, seven patients (7.1%) were Stage IIb and six patients (6.1%) were Stage III.
  • Cases with a preoperative biopsy showing atypical hyperplasia or well differentiated adenocarcinoma should have a preoperative MRI scan or preferably an intraoperative frozen section examination to identify those cases with adverse pathological features which need to be fully staged with pelvic and paraaortic lymphadenectomy.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Uterine Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19317254.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Italy
  •  go-up   go-down


22. Mittal K, Da Costa D: Endometrial hyperplasia and carcinoma in endometrial polyps: clinicopathologic and follow-up findings. Int J Gynecol Pathol; 2008 Jan;27(1):45-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial hyperplasia and carcinoma in endometrial polyps: clinicopathologic and follow-up findings.
  • 1) to evaluate findings in follow-up hysterectomy specimens after a diagnosis of complex atypical hyperplasia or carcinoma in endometrial polyps (EMPs) for possible significance in management strategies; and 2)to identify features in these polyps, that are predictive of the presence of endometrial hyperplasia or carcinoma in subsequent hysterectomy.
  • Records of all cases of EMPs with endometrial hyperplasia were retrieved from the files of New York University Medical Center from 1993 to 2005.
  • Of the 29 patients with complex atypical hyperplasia within the polyp, 19 out of 29 (66%) patients had hyperplasia of the non-polyp endometrium, and adenocarcinoma was observed in 9 out of 29 (31%) patients on follow-up hysterectomy.
  • The percentage of polyp area involved by the hyperplasia was predictive of finding endometrial disorder in subsequent hysterectomy (P = 0.005).
  • Of the 8 patients with adenocarcinoma in situ (AIS) within the polyp 3 (38%) had myoinvasive adenocarcinoma.
  • In contrast, in cases without AIS, 4 out of 21 (19%) had myoinvasive adenocarcinoma in follow-up hysterectomy.
  • Eight of the nine cases with carcinoma in endometrial polyp had endometrial pathology on hysterectomy.
  • Approximately two thirds of the patients with hyperplasia and 90% of patients with adenocarcinoma in endometrial polyps show endometrial pathology on subsequent hysterectomy.
  • The above findings reinforce the need for hysterectomy especially in postmenopausal women with atypical complex hyperplasia or carcinoma in endometrial polyps even if these changes appear confined to the polyp in initial sampling.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma in Situ / pathology. Endometrial Hyperplasia / pathology. Endometrial Neoplasms / pathology. Polyps / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18156974.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Oztürk HB, Vural B, Calışkan E, Solakoğlu S: Effect of GnRH analogues and octreotide treatment on apoptosis and the cell proliferation of endometrium adenocarcinoma cell lines. J Turk Ger Gynecol Assoc; 2010;11(3):131-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of GnRH analogues and octreotide treatment on apoptosis and the cell proliferation of endometrium adenocarcinoma cell lines.
  • OBJECTIVE: The aim of this study was to compare apoptotic and antiproliferative effects of gonadotropin-releasing hormone analogues and their combination with octeotide on endometrioid endometrial cancer cell lines.
  • MATERIAL AND METHOD: Women diagnosed with endometrioid adenocarcinoma at the department of Gynecology and Obstetric of Kocaeli University Medical School were included in this research.
  • Endometrium cancer cell lines obtained from three patients were used for this study.
  • CONCLUSION: GnRH analogues appears to have a direct effect, enhancing the apoptotic index and decreasing the cell proliferation in endometrial adenocancer cell lines.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24591918.001).
  • [ISSN] 1309-0399
  • [Journal-full-title] Journal of the Turkish German Gynecological Association
  • [ISO-abbreviation] J Turk Ger Gynecol Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  • [Other-IDs] NLM/ PMC3939219
  • [Keywords] NOTNLM ; Endometrial cancer / apoptosis / cell proliferation / gonadotropin-releasing hormone analogues / octreotide
  •  go-up   go-down


24. Mihalcea D, Aursulesei D: [Myometrial invasion as a prognostic factor in endometrial adenocarcinoma]. Rev Med Chir Soc Med Nat Iasi; 2009 Jan-Mar;113(1):136-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Myometrial invasion as a prognostic factor in endometrial adenocarcinoma].
  • [Transliterated title] Invazia miometrială-factor de prognostic în adenocarcinomul endometrial.
  • Myometrial invasion is one of the most important prognostic factors in endometrial cancer.
  • MATERIAL AND METHOD: We have studied a cohort of 62 patients with endometrial cancer who underwent surgery in 4-th Gynecology Clinic of "Cuza Vodă" Hospital, Iaşi between 1997-2008.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Myometrium / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21495308.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


25. Ibáñez Pinto A, Fernández Salgado E, Castro Ortiz E, Baltar Arias R, Vázquez Vázquez S, Ledo Barro L, Vázquez San Luis J, Vázquez Astray E: [Gastrointestinal bleeding of obscure origin caused by a metastatic endometrial adenocarcinoma. Response to hormonal therapy]. Gastroenterol Hepatol; 2007 Nov;30(9):530-4
MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastrointestinal bleeding of obscure origin caused by a metastatic endometrial adenocarcinoma. Response to hormonal therapy].
  • [Transliterated title] Hemorragia digestiva de origen incierto por un adenocarcinoma endometrial metastásico. Respuesta al tratamiento hormonal.
  • BACKGROUND: Endometrial cancer (EC) is the most common gynecologic malignancy.
  • CASE REPORT: We report the case of a 77-year-old woman who presented with intermittent gastrointestinal bleeding 2 years after treatment of stage IIb EC.
  • Biopsy of a subcutaneus nodule showed fibroadipose tissue infiltrated by an EC.
  • A computed tomography scan showed extensive lymphatic, abdominal and pelvic recurrence of the cancer.
  • Control of bleeding and a 22-month survival were obtained after treatment with oral medroxyprogesterone acetate.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Carcinoma, Endometrioid / secondary. Endometrial Neoplasms / pathology. Gastrointestinal Hemorrhage / etiology. Medroxyprogesterone Acetate / therapeutic use. Pelvic Neoplasms / secondary. Peritoneal Neoplasms / secondary. Retroperitoneal Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17980130.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; C2QI4IOI2G / Medroxyprogesterone Acetate
  • [Number-of-references] 19
  •  go-up   go-down


26. Kurotaki T, Kokoshima H, Kitamori F, Kitamori T, Tsuchitani M: A case of adenocarcinoma of the endometrium extending into the leiomyoma of the uterus in a rabbit. J Vet Med Sci; 2007 Sep;69(9):981-4
MedlinePlus Health Information. consumer health - Uterine Fibroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of adenocarcinoma of the endometrium extending into the leiomyoma of the uterus in a rabbit.
  • In a pet rabbit, 2 tumor masses one on each horn were macroscopically seen in the wall of the uterus.
  • The tumor was diagnosed as an adenocarcinoma of the endometrium.
  • While adenocarcinoma cells formed a protrusive mass in the uterine lumen, they also showed an extension into the leiomyoma of the myometrium.
  • By immunohistochemistry, adenocarcinoma stained positive for cytokeratin (MNF116) and leiomyoma stained positive for smooth muscle actin, showing a substantial difference in the cytological nature of these tumor cells.
  • The results may give a further evidence supporting the narrative of the tumor development that an adenocarcinoma of the endometrium extended into leiomyoma of the uterus.

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17917388.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


27. Sánchez Anguiano LF, Puente Ledesma L, Lares Bayona EF, Milla Villeda RH: [Estrogenic receptors in hyperplasia and endometrial adenocarcinoma: immunohystochemical study with image analysis]. Ginecol Obstet Mex; 2007 Sep;75(9):501-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Estrogenic receptors in hyperplasia and endometrial adenocarcinoma: immunohystochemical study with image analysis].
  • [Transliterated title] Receptores de estrógenos en la hiperplasia y el adenocarcinoma de endometrio: estudio inmunohistoquímico con análisis de imagen.
  • BACKGROUND: The endometrium is a very dynamic organ that experience several half-full processes by the ovarian secretion of estradiol and progesterone.
  • The effect of hormones steroids, in the epithelial cells, endoteliales and estromales of the endometrium, is influenced by receptors of estrogens and progesterone.
  • OBJECTIVE: determine if there are any differences in the density of the estrogen receptors (ER) between the normal endometrial, the simple and complex hyperplasia, the atypical hyperplasia and the.
  • We included 143 samples that were knit together in 5 categories of the following way: Normal endometrial (n = 38), Simple hyperplasia (n = 58), Complex hyperplasia (n = 22), Atypical hyperplasia (n = 9), Adenocarcinoma (n = 16).
  • RESULTS: there were no statistical significant differences on the cell density with ER between the normal endometrial and the simple and complex hyperplasia.
  • The estrogen receptors are decreased in the atypical hyperplasia and the endometrial adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / chemistry. Endometrial Neoplasms / chemistry. Receptors, Estrogen / analysis
  • [MeSH-minor] Endometrial Hyperplasia. Female. Humans. Immunohistochemistry. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18293624.001).
  • [ISSN] 0300-9041
  • [Journal-full-title] Ginecología y obstetricia de México
  • [ISO-abbreviation] Ginecol Obstet Mex
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Receptors, Estrogen
  •  go-up   go-down


28. Rice LW, Stone RL, Xu M, Galgano M, Stoler MH, Everett EN, Jazaeri AA: Biologic targets for therapeutic intervention in endometrioid endometrial adenocarcinoma and malignant mixed müllerian tumors. Am J Obstet Gynecol; 2006 Apr;194(4):1119-26; discussion 1126-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biologic targets for therapeutic intervention in endometrioid endometrial adenocarcinoma and malignant mixed müllerian tumors.
  • OBJECTIVE: The purpose of this study was to investigate the AKT signaling cascade in endometrial cancers and to assess its therapeutic potential.
  • STUDY DESIGN: Western blotting and immunohistochemistry were used to investigate the expression of estrogen receptor, progesterone receptor, HER2, AKT, and 4EBP1 proteins in 27 atrophic endometria, 31 grade 1 and 24 grade 3 endometrioid endometrial cancers, and 19 malignant mixed müllerian tumors.
  • RESULTS: Malignant mixed müllerian tumors and grade 3 endometrioid endometrial cancers demonstrated higher levels of AKT and 4EBP1 activation and hormone receptor loss compared with grade 1 endometrioid endometrial cancers and atrophic samples.
  • In endometrial cancer cell-lines, AKT cascade inhibitors decreased cell proliferation by apoptosis and cell cycle arrest.
  • CONCLUSION: AKT cascade activation in grade 3 endometrioid endometrial cancers and malignant mixed müllerian tumors is a novel finding.
  • [MeSH-major] Carcinoma, Endometrioid / drug therapy. Endometrial Neoplasms / drug therapy. Mixed Tumor, Mullerian / drug therapy. Oncogene Protein v-akt / antagonists & inhibitors

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16580307.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA44579
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.1 / Oncogene Protein v-akt
  •  go-up   go-down


29. Arai T, Watanabe J, Kawaguchi M, Kamata Y, Nishimura Y, Jobo T, Kuramoto H: Clear cell adenocarcinoma of the endometrium is a biologically distinct entity from endometrioid adenocarcinoma. Int J Gynecol Cancer; 2006 Jan-Feb;16(1):391-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell adenocarcinoma of the endometrium is a biologically distinct entity from endometrioid adenocarcinoma.
  • Clear cell adenocarcinoma (CCA) of the endometrium has a poor prognosis, although the biologic features of this rare tumor are not clear.
  • Thirteen cases of CCA were compared with cases of endometrioid adenocarcinoma (EMA) of the endometrium.
  • Immunohistochemical staining for p53; Ki-67; cyclins A, D1, and E; E-cadherin; progesterone receptor (PR)-A and PR-B; P-glycoprotein; MLH1; and MSH2 was performed.
  • No CCAs were positive for PR-A and PR-B.
  • The mechanism of cell-cycle regulation in endometrial CCA is different from that in EMA and may influence its malignant potential.
  • Endometrial CCA is a distinct entity from EMA.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Biomarkers, Tumor / analysis. Cadherins / analysis. Carcinoma, Endometrioid / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy, Needle. Cohort Studies. Cyclin A / analysis. Cyclin D1 / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Middle Aged. Neoplasm Staging. Retrospective Studies. Sensitivity and Specificity. Tumor Suppressor Protein p53

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445664.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Cyclin A; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; 136601-57-5 / Cyclin D1
  •  go-up   go-down


30. Castilho MS, Jacinto AA, Viani GA, Campana A, Carvalho J, Ferrigno R, Novaes PE, Fogaroli RC, Salvajoli JV: Intensity Modulated Radiotherapy (IMRT) in the postoperative treatment of an adenocarcinoma of the endometrium complicated by a pelvic kidney. Radiat Oncol; 2006;1:44

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity Modulated Radiotherapy (IMRT) in the postoperative treatment of an adenocarcinoma of the endometrium complicated by a pelvic kidney.
  • BACKGROUND: Pelvic Radiotherapy (RT) as a postoperative treatment for endometrial cancer improves local regional control.
  • CASE: We report on a 50 year-old patient with a serous-papiliferous adenocarcinoma of the uterus who was submitted to surgical treatment without lymph node sampling followed by Brachytherapy, and Chemotherapy.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Endometrial Neoplasms / radiotherapy. Endometrial Neoplasms / surgery. Radiotherapy, Intensity-Modulated / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Transplantation. 2000 Sep 15;70(5):844-6 [11003368.001]
  • [Cites] Int J Gynaecol Obstet. 2000 Aug;70(2):209-62 [11041682.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):1004-9 [14575831.001]
  • [Cites] Gynecol Oncol. 2004 Jan;92(1):376-9 [14751190.001]
  • [Cites] J Urol. 1980 May;123(5):766-7 [7420573.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Oct;19(4):977-83 [1976615.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22 [2032882.001]
  • [Cites] Int J Gynaecol Obstet. 1993 Aug;42(2):174-6 [7901069.001]
  • [Cites] Transplantation. 1994 Aug 27;58(4):520-2 [8073523.001]
  • [Cites] Gynecol Oncol. 1995 Oct;59(1):151-5 [7557603.001]
  • [Cites] J Surg Oncol. 1996 Sep;63(1):57-60 [8841468.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):834-8 [15927414.001]
  • [Cites] Radiother Oncol. 2005 Oct;77(1):11-7 [16024116.001]
  • (PMID = 17116263.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1660561
  • [General-notes] NLM/ Original DateCompleted: 20070809
  •  go-up   go-down


31. Talvensaari-Mattila A, Santala M, Soini Y, Turpeenniemi-Hujanen T: Prognostic value of matrix metalloproteinase-2 (MMP-2) expression in endometrial endometrioid adenocarcinoma. Anticancer Res; 2005 Nov-Dec;25(6B):4101-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of matrix metalloproteinase-2 (MMP-2) expression in endometrial endometrioid adenocarcinoma.
  • Matrix metalloproteinase-2 (MMP-2), a member of the zinc-dependent metalloproteinase gene family, plays an important role in cancer invasion and metastasis.
  • The current study aimed to evaluate whether the expression of MMP-2 is associated with survival in patients with endometrial endometrioid adenocarcinoma.
  • The MMP-2 immunoreactive protein was evaluated from endometrioid adenocarcinoma of the endometrium in 112 patients treated at Oulu University Hospital, Finland.
  • These data suggest that MMP-2 immunostaining negativity might be linked with a favourable prognosis in endometrial endometrioid adenocarcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / enzymology. Endometrial Neoplasms / enzymology. Matrix Metalloproteinase 2 / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16309203.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


32. Wicherek L, Popiela TJ, Galazka K, Dutsch-Wicherek M, Opławski M, Basta A, Klimek M: Metallothionein and RCAS1 expression in comparison to immunological cells activity in endometriosis, endometrial adenocarcinoma and endometrium according to menstrual cycle changes. Gynecol Oncol; 2005 Dec;99(3):622-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metallothionein and RCAS1 expression in comparison to immunological cells activity in endometriosis, endometrial adenocarcinoma and endometrium according to menstrual cycle changes.
  • OBJECTIVE: Endometrium is a specialized organ in which phenomena controlling the level of cell proliferation and apoptosis are marked.
  • The aim of our study was to determine the presence of proteins involved in apoptosis and proliferation: RCAS1, MT and the number of CD56-positive cells and their activity to elucidate their possible role in the development of adenocarcinoma and endometriosis.
  • RESULTS: We found that endometrium during secretory menstrual cycle phase is characterized by significantly higher RCAS1 and higher MT expression than in proliferative phase.
  • Endometrial adenocarcinoma was characterized by significantly increased RCAS1 expression, while MT expression was comparable to the level found in the secretory phase.
  • CONCLUSIONS: The ability of endometrium to determine cytotoxic activity (RCAS1 expression changes) and high protection against DNA damage (MT expression) with concomitant changes in the number of immune cells and their activity, observed in normal endometrium during the menstrual cycle phases seems to be fundamental for pathological features of endometrial adenocarcinoma and endometriosis.
  • [MeSH-major] Adenocarcinoma / immunology. Antigens, Neoplasm / biosynthesis. Endometrial Neoplasms / immunology. Endometriosis / immunology. Endometrium / immunology. Menstrual Cycle / immunology. Metallothionein / biosynthesis

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16112719.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD56; 0 / Antigens, Differentiation, T-Lymphocyte; 0 / Antigens, Neoplasm; 0 / CD69 antigen; 0 / EBAG9 protein, human; 0 / Lectins, C-Type; 9038-94-2 / Metallothionein
  •  go-up   go-down


33. Shaco-Levy R, Piura B: Endometrioid endometrial adenocarcinoma recurring as carcinosarcoma. J Obstet Gynaecol Res; 2008 Apr;34(2):279-82

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid endometrial adenocarcinoma recurring as carcinosarcoma.
  • Müllerian carcinosarcoma is currently regarded as a metaplastic (sarcomatous) carcinoma.
  • Only five cases of pure ovarian adenocarcinoma recurring as carcinosarcoma have been documented in the literature.
  • There are no documented cases of endometrial adenocarcinoma recurring as metaplastic carcinoma.
  • We report of a case of endometrial adenocarcinoma, endometrioid type, recurring as metaplastic carcinoma showing sarcomatous differentiation.
  • The tumor evolution in this case supports the prevailing opinion that Müllerian carcinosarcomas are derived from carcinomas and represent tumor progression.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Carcinosarcoma / pathology. Endometrial Neoplasms / pathology. Neoplasm Recurrence, Local / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18412798.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


34. Wallace AE, Gibson DA, Saunders PT, Jabbour HN: Inflammatory events in endometrial adenocarcinoma. J Endocrinol; 2010 Aug;206(2):141-57
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory events in endometrial adenocarcinoma.
  • Endometrial adenocarcinoma is the most common gynaecological malignancy in western countries.
  • Many of the established risk factors for developing endometrial cancer are associated with excess exposure to oestrogen unopposed by progesterone.
  • However, a number of risk factors also promote inflammation, another feature proposed to influence cancer development.
  • The human cycling endometrium undergoes regular and cyclical episodes of inflammation.
  • Moreover, hormonal and genetic changes that occur early in the development of endometrial adenocarcinoma can exacerbate the local inflammatory environment.
  • Via alterations in the expression of local mediators and immune cell function, these may contribute to the development of endometrial cancer.
  • This review discusses the contribution of inflammation to the initiation and progression of endometrial adenocarcinoma.
  • Manipulation of inflammatory pathways may therefore represent a therapeutic target in endometrial adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Inflammation

  • Hazardous Substances Data Bank. PROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20406782.001).
  • [ISSN] 1479-6805
  • [Journal-full-title] The Journal of endocrinology
  • [ISO-abbreviation] J. Endocrinol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MRC/ MC/ U127685844; United Kingdom / Medical Research Council / / MRC/ MC/ U127684438; United Kingdom / Medical Research Council / / MRC/ U.1276.00.002.00005.01 (85844); United Kingdom / Medical Research Council / / U.1276.00.004.00002.01; United Kingdom / Medical Research Council / / U1276.00.002.00005.01
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Androgens; 0 / Chemokines; 0 / Cytokines; 0 / Estrogens; 0 / Glucocorticoids; 0 / KRAS protein, human; 0 / NF-kappa B; 0 / Prostaglandins; 0 / Proto-Oncogene Proteins; 4G7DS2Q64Y / Progesterone; EC 3.1.3.67 / PTEN Phosphohydrolase; EC 3.1.3.67 / PTEN protein, human; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras); EC 3.6.5.2 / ras Proteins
  • [Number-of-references] 190
  •  go-up   go-down


35. Tantbirojn P, Triratanachat S, Trivijitsilp P, Niruthisard S: Comparison between adenocarcinoma in both endocervical and endometrial specimens from fractional curettage and pathologic findings in subsequent hysterectomy specimens. J Med Assoc Thai; 2008 Sep;91(9):1313-7
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison between adenocarcinoma in both endocervical and endometrial specimens from fractional curettage and pathologic findings in subsequent hysterectomy specimens.
  • OBJECTIVE: To evaluate the hysterectomy specimen findings in the patients who underwent fractional curettage (F&C) with presence of adenocarcinoma in both endocervical and endometrial specimens.
  • MATERIAL AND METHOD: Forty-one patients who had adenocarcinoma in both endocervical and endometrial specimens from F&C and underwent subsequent hysterectomy for surgical staging without pre-operative radiotherapy or chemotherapy at King Chulalongkorn Memorial Hospital between 1999 and 2007 were evaluated Histologic slides from both F&C and hysterectomy specimens were reviewed and assessed All cases of endometrial adenocarcinoma with cervical involvement (stage 2) in hysterectomy specimens were also assessed and compared to the results in F&C specimens.
  • RESULTS: Fifteen patients (36.6%) with both positive endocervical and endometrial specimens from F&C were diagnosed as endometrial adenocarcinoma within uterine cavity with lower uterine segment involvement.
  • Only 34.1% of cases were endometrial carcinomas with cervical involvement.
  • In the 35 cases with endometrial carcinoma stage 2, 60% had adenocarcinoma in both endocervical and endometrial specimens from F&C.
  • CONCLUSION: In the patients who had adenocarcinoma in both endocervical and endometrial specimens from fractional curettage, the most common final pathological diagnosis from hysterectomy specimens was endometrial adenocarcinoma within uterine cavity with lower uterine segment involvement.
  • Therefore, only 60% of endometrial carcinoma stage 2 revealed positive adenocarcinoma in both endocervical and endometrial specimens from fractional curettage.
  • [MeSH-major] Adenocarcinoma / pathology. Cervix Uteri / pathology. Dilatation and Curettage. Endometrial Neoplasms / pathology. Endometrium / pathology. Hysterectomy

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18843857.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


36. Takeuchi K, Kitazawa S, Hamanishi S, Inagaki M, Murata K: A case of alpha-fetoprotein-producing adenocarcinoma of the endometrium with a hepatoid component as a potential source for alpha-fetoprotein in a postmenopausal woman. Int J Gynecol Cancer; 2006 May-Jun;16(3):1442-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of alpha-fetoprotein-producing adenocarcinoma of the endometrium with a hepatoid component as a potential source for alpha-fetoprotein in a postmenopausal woman.
  • Although case reports of alpha-fetoprotein (AFP)-producing adenocarcinoma other than hepatocellular carcinoma have gradually increased in number, AFP-producing adenocarcinoma of the endometrium is very rare.
  • Radiologic imaging and endoscopy did not provide evidence of any primary carcinoma in the liver and gastrointestinal tract.
  • To investigate the unknown origin of high AFP, Pap smear of the endometrium followed by fractional curettage was performed and revealed adenocarcinoma of the endometrium.
  • Histologic study showed a mixture of major AFP-negative endometrioid adenocarcinoma and minor medullary proliferation of the AFP-positive hepatoid adenocarcinoma cells with eosinophilic cytoplasm and hyaline globules.
  • The possible existence of AFP-producing adenocarcinoma of the endometrium should be considered in a postmenopausal woman even if there is no vaginal bleeding, when AFP-producing tumor is clinically suspected and the imaging studies fail to confirm the diagnosis.
  • [MeSH-major] Carcinoma, Endometrioid / secretion. Carcinoma, Hepatocellular / secondary. Endometrial Neoplasms / secretion. alpha-Fetoproteins / secretion

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803544.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  • [Number-of-references] 10
  •  go-up   go-down


37. McKenney JK, Longacre TA: Low-grade endometrial adenocarcinoma: a diagnostic algorithm for distinguishing atypical endometrial hyperplasia and other benign (and malignant) mimics. Adv Anat Pathol; 2009 Jan;16(1):1-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade endometrial adenocarcinoma: a diagnostic algorithm for distinguishing atypical endometrial hyperplasia and other benign (and malignant) mimics.
  • The distinction between endometrial hyperplasia and well-differentiated adenocarcinoma of the endometrium continues to be a difficult differential diagnosis in surgical pathology.
  • Evidence-based diagnostic criteria for well-differentiated endometrial adenocarcinoma focus on histologic features that predict myoinvasion in the hysterectomy specimen.
  • Application of these 2 criteria in problematic endometrial proliferations allows stratification of patients into 3 risk categories: very low risk (< 0.05% risk of myoinvasion at hysterectomy)=complex atypical hyperplasia; intermediate risk (5.5% risk of myoinvasion at hysterectomy)=complex atypical hyperplasia, cannot exclude well-differentiated adenocarcinoma (borderline); and high risk (20% risk of myoinvasion at hysterectomy)=well-differentiated adenocarcinoma.
  • In order to optimize the use of these diagnostic criteria, a variety of gland forming lesions that may mimic well-differentiated endometrioid adenocarcinoma must first be excluded.
  • In addition, unusual morphologic patterns of low-grade endometrioid adenocarcinoma should be recognized, as they may cause confusion with other, higher grade (and therefore, more clinically aggressive) endometrial processes.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Endometrium / pathology. Uterine Diseases / pathology
  • [MeSH-minor] Algorithms. Cell Division. Diagnosis, Differential. Female. Humans. Hyperplasia. Kinetics. Metaplasia / pathology. Neoplasm Invasiveness. Risk Assessment

  • MedlinePlus Health Information. consumer health - Uterine Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19098463.001).
  • [ISSN] 1533-4031
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 58
  •  go-up   go-down


38. Tretheway D, Gebhardt JG, Dogra VS, Schiffhauer LM: Metastatic versus primary oncocytic papillary adenocarcinoma of the endometrium: a report of a case and review of the literature. Int J Gynecol Pathol; 2009 May;28(3):256-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic versus primary oncocytic papillary adenocarcinoma of the endometrium: a report of a case and review of the literature.
  • We report a case of an oncocytic papillary adenocarcinoma of the endometrium in an 89-year-old female with vaginal bleeding.
  • Imaging studies revealed lesions in the uterus, kidneys, pancreas, gluteus, and an enlarged portacaval lymph node.
  • Diagnostic workup included an endometrial biopsy which showed malignant, oncocytic cells in a predominantly papillary pattern.
  • The cells were negative for cytokeratin 903, CAM 5.2, progesterone receptor, CD10, RCC Marker, CA-125, c-kit, and vimentin.
  • Consultation with experts in Gynecologic and Genitourinary pathology returned a diagnosis of "adenocarcinoma compatible with metastatic renal cell carcinoma"--an intriguing possibility worthy of further exploration.
  • To our knowledge, there are no reports in the literature of metastatic oncocytic papillary renal cell carcinoma to the endometrium.
  • The clinical and pathologic features of oncocytic papillary endometrial lesions, including primary and metastatic processes, are reviewed.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Endometrial Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620943.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 13
  •  go-up   go-down


39. Cannon GM, Geye H, Terakedis BE, Kushner DM, Connor JP, Hartenbach EM, Bradley KA: Outcomes following surgery and adjuvant radiation in stage II endometrial adenocarcinoma. Gynecol Oncol; 2009 May;113(2):176-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes following surgery and adjuvant radiation in stage II endometrial adenocarcinoma.
  • PURPOSE: To evaluate locoregional control, disease free survival, and overall survival in patients treated with surgery and adjuvant radiation for stage II adenocarcinoma of the endometrium.
  • MATERIALS AND METHODS: All patients receiving adjuvant radiation at the University of Wisconsin following surgery for FIGO stage II adenocarcinoma of the endometrium between January 1991 and December 2006 were retrospectively reviewed.
  • RESULTS: Between January 1991 and December 2006, 71 patients with FIGO stage II adenocarcinoma of the endometrium (23 stage IIA, 48 stage IIB) received adjuvant radiation at the University of Wisconsin.
  • DISCUSSION: Local recurrence rates remain low after surgery and adjuvant radiation therapy for stage II endometrial cancer using a combination of VB and EXT tailored to the surgical and pathologic features.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Endometrial Neoplasms / radiotherapy. Endometrial Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19217147.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Puisoru M, Fatu C, Fatu IC: Histochemical evaluation of angiogenesis in endometrial adenocarcinoma. Ann Anat; 2006 May;188(3):255-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histochemical evaluation of angiogenesis in endometrial adenocarcinoma.
  • In this study, vascularization of tumor tissue was evaluated quantitatively in 36 cases of stage I endometrial adenocarcinoma.
  • The goal of this study was to evaluate whether the microvessel density correlates with the invasion potential of endometrial adenocarcinoma.
  • The results show an increase in the number of endothelial cells at different stages in endometrial adenocarcinoma stage I and a strong positive correlation between the endothelial-to-stromal ratio and tumor grading.
  • [MeSH-major] Adenocarcinoma / blood supply. Adenocarcinoma / pathology. Endometrial Neoplasms / blood supply. Endometrial Neoplasms / pathology. Neovascularization, Pathologic / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16711164.001).
  • [ISSN] 0940-9602
  • [Journal-full-title] Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft
  • [ISO-abbreviation] Ann. Anat.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


41. Jayakrishnan K, Anupama R, Koshy A, Raju R: Endometrial carcinoma in a young subfertile woman with polycystic ovarian syndrome. J Hum Reprod Sci; 2010 Jan;3(1):38-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial carcinoma in a young subfertile woman with polycystic ovarian syndrome.
  • Adenocarcinoma of the endometrium is a morbid condition in women under 40 years of age with an incidence of 25%.
  • However, patients with anovulatory polycystic ovarian syndrome are at risk of developing endometrial carcinoma.
  • In young women with menstrual abnormalities and polycystic ovarian disease and/or infertility, an endometrial evaluation should be performed.
  • Carcinoma endometrium should be kept in mind while evaluating young women with polycystic ovary syndrome for abnormal uterine bleeding.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2008 Dec;111(3):579-82 [18395778.001]
  • [Cites] Fertil Steril. 2008 Mar;89(3):724.e1-3 [17570366.001]
  • [Cites] Semin Reprod Med. 2008 Jan;26(1):62-71 [18181084.001]
  • [Cites] J Clin Oncol. 2007 Jul 1;25(19):2798-803 [17602085.001]
  • [Cites] Int J Gynecol Cancer. 2005 Jul-Aug;15(4):657-62 [16014120.001]
  • [Cites] BJOG. 2005 Mar;112(3):317-20 [15713146.001]
  • [Cites] Gynecol Oncol. 2000 Oct;79(1):129-32 [11006045.001]
  • [Cites] Fertil Steril. 1996 Jun;65(6):1083-9 [8641477.001]
  • [Cites] Endocrinology. 1995 Jun;136(6):2531-7 [7750475.001]
  • [Cites] Endocr Rev. 1990 Aug;11(3):443-53 [2226350.001]
  • [Cites] Br J Cancer. 1988 Feb;57(2):205-12 [3358913.001]
  • [Cites] Lancet. 2003 May 24;361(9371):1810-2 [12781553.001]
  • [Cites] Lancet. 2002 Jul 20;360(9328):235 [12133671.001]
  • [Cites] Hum Reprod. 1997 Aug;12(8):1649-53 [9308787.001]
  • (PMID = 20607008.001).
  • [ISSN] 1998-4766
  • [Journal-full-title] Journal of human reproductive sciences
  • [ISO-abbreviation] J Hum Reprod Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2890909
  • [Keywords] NOTNLM ; Endometrial adenocarcinoma / infertility / polycystic ovaries
  •  go-up   go-down


42. Manchana T, Khemapech N: Endometrial adenocarcinoma in young Thai women. Asian Pac J Cancer Prev; 2008 Apr-Jun;9(2):283-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial adenocarcinoma in young Thai women.
  • OBJECTIVE: To evaluate the clinicopathological characteristics and survival analysis in endometrial adenocarcinoma women younger than the age of 40 years compare to older women.
  • METHODS: Medical records of 423 endometrial adenocarcinoma patients who received primary surgical treatment at King Chulalongkorn Memorial Hospital during 1996-2005 were reviewed.
  • RESULTS: Up to 10% (42/423) of endometrial adenocarcinoma patients were younger than the age of 40 years.
  • Moreover, synchronous ovarian cancer seemed to be higher in young patients (7.1% and 2.9%, p > .05).
  • CONCLUSIONS: Obesity was the only independent factor associated with endometrial adenocarcinoma in young patients.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18712975.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


43. Smith DC, Macdonald OK, Lee CM, Gaffney DK: Survival impact of lymph node dissection in endometrial adenocarcinoma: a surveillance, epidemiology, and end results analysis. Int J Gynecol Cancer; 2008 Mar-Apr;18(2):255-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival impact of lymph node dissection in endometrial adenocarcinoma: a surveillance, epidemiology, and end results analysis.
  • The therapeutic benefit of lymph node dissection (LND) in women with endometrial cancer remains controversial.
  • Data were obtained from the Surveillance, Epidemiology, and End Results program of the US National Cancer Institute for the years 1988-2003.
  • Women with adenocarcinoma of the endometrium who underwent surgery as primary management of their disease were eligible.
  • On multivariate analysis, presence of LND was associated with overall and uterine-specific survival benefits with hazard ratios (HR) of 0.81 (P < 0.0001) and 0.78 (P < 0.0001) and removal of greater than 11 lymph nodes (LN) associated with a HR of 0.74 (P < 0.0001) and 0.69 (P < 0.0001), respectively.
  • Further multivariate analyses demonstrated greater than 11 LN to associate with all other cause-specific and cardiac-specific survival benefits, with HR of 0.77 (P < 0.0001) and 0.82 (P = 0.0062), respectively.
  • We conclude that the presence of LND and increased number of nodes dissected predicted for improved overall and uterine-specific survival in women with adenocarcinoma of the endometrium.
  • [MeSH-major] Endometrial Neoplasms / mortality. Lymph Node Excision / mortality
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Aged. Female. Humans. Middle Aged. SEER Program. Survival Analysis. United States / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17624991.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Lomo L, Nucci MR, Lee KR, Lin MC, Hirsch MS, Crum CP, Mutter GL: Histologic and immunohistochemical decision-making in endometrial adenocarcinoma. Mod Pathol; 2008 Aug;21(8):937-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histologic and immunohistochemical decision-making in endometrial adenocarcinoma.
  • Diffuse p53 immunostaining distinguishes 85% of serous (Type II) from endometrioid (Type I) carcinomas and is an independent marker for poor prognosis.
  • Interobserver reproducibility for the diagnosis of these entities, as well as selection and prediction of p53 immunostaining results, is unknown.
  • A subset of endometrial cancers do not readily fit within a two-class system and can be culled from cases that (1) do not achieve interobserver concordance and (2) are more likely to be chosen for p53 immunostaining and (3) are more likely to stain positive for p53.
  • Because p53 is an important marker for endometrial adenocarcinoma outcome, and cannot be predicted in advance in indeterminate cases, p53 immunostaining should be employed in cases with observer disagreement in a binary system.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cystadenocarcinoma, Serous / pathology. Endometrial Neoplasms / pathology. Tumor Suppressor Protein p53 / analysis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18500258.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


45. Yoshida M, Watanabe G, Shirota M, Maekawa A, Taya K: Reduction of primordial follicles caused by maternal treatment with busulfan promotes endometrial adenocarcinoma development in donryu rats. J Reprod Dev; 2005 Dec;51(6):707-14
Hazardous Substances Data Bank. BUSULFAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduction of primordial follicles caused by maternal treatment with busulfan promotes endometrial adenocarcinoma development in donryu rats.
  • Ovarian dysfunction leading to hormonal imbalance plays a crucial role in uterine carcinogenesis in rats as well as women.
  • However, the effects of a reduction in primordial follicles at birth on uterine adenocarcinoma development have hitherto not been determined.
  • The present study was therefore conducted using female Donryu rats, a high incidence rat strain of uterine adenocarcinoma.
  • The incidence of uterine adenocarcinomas and multiplicity of uterine neoplastic lesions were significantly increased by the 5.0 mg/kg, but not the 2.5 mg/kg busulfan treatment.
  • These results provide evidence that the reduction of primordial follicles promotes uterine adenocarcinoma development in rats in association with an earlier occurrence of the persistent estrus status.
  • [MeSH-major] Adenocarcinoma / etiology. Antineoplastic Agents, Alkylating / pharmacology. Busulfan / pharmacology. Endometrial Neoplasms / etiology. Ovarian Diseases / chemically induced. Ovarian Follicle / drug effects

  • MedlinePlus Health Information. consumer health - Ovarian Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16177545.001).
  • [ISSN] 0916-8818
  • [Journal-full-title] The Journal of reproduction and development
  • [ISO-abbreviation] J. Reprod. Dev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Gonadal Steroid Hormones; G1LN9045DK / Busulfan
  •  go-up   go-down


46. Ashton-Sager A, Paulino AF, Afify AM: GLUT-1 is preferentially expressed in atypical endometrial hyperplasia and endometrial adenocarcinoma. Appl Immunohistochem Mol Morphol; 2006 Jun;14(2):187-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GLUT-1 is preferentially expressed in atypical endometrial hyperplasia and endometrial adenocarcinoma.
  • Although the aberrant expression of GLUT-1 has been reported in a wide spectrum of epithelial malignancies, its possible correlation with the malignant transformation of endometrial epithelium has not been clearly established.
  • The purpose of this study was to evaluate the extent to which benign, hyperplastic, atypical, and malignant endometrial epithelia express GLUT-1.
  • The authors examined the IHC expression of GLUT-1 in cases of proliferative endometrium (n=12), secretory endometrium (n=10), endometrial polyps (n=10), adenomyosis (n=18), simple hyperplasia (n=14), complex hyperplasia without atypia (n=17), complex hyperplasia with atypia (n=17), and adenocarcinoma (n=31).
  • All cases from proliferative endometrium, secretory endometrium, adenomyosis, and simple hyperplasia and 90% (9/10 cases) of the endometrial polyps were negative for GLUT-1.
  • GLUT-1 was expressed in 24% (4/17 cases) of complex hyperplasia without atypia, 71% (12/17 cases) of complex hyperplasia with atypia, and 90% (28/31 cases) of adenocarcinomas.
  • The authors conclude that GLUT-1 is preferentially expressed in complex hyperplasia with atypia and in adenocarcinoma and that GLUT-1 immunostaining is useful in distinguishing benign hyperplasia from hyperplasia strongly associated with malignancy.
  • These data suggest that the expression of GLUT-1 transporter may be closely related to the malignant transformation of epithelial endometrial tumors by supporting their increased need for glucose metabolism.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16785788.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucose Transporter Type 1
  •  go-up   go-down


47. Nabli H, Tuller E, Sharpe-Timms KL: Haptoglobin expression in endometrioid adenocarcinoma of the uterus. Reprod Sci; 2010 Jan;17(1):47-55
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Haptoglobin expression in endometrioid adenocarcinoma of the uterus.
  • OBJECTIVE: Elevated serum haptoglobin (Hp) concentrations have been reported in patients with malignant diseases.
  • We have shown that Hp is produced by and localizes only in the stroma and not the epithelium of endometriotic lesions, which share many characteristics of carcinoma.
  • Furthermore, Hp mRNA and protein are found exclusively in the stroma of eutopic endometrium from women with endometriosis and not those without endometriosis.
  • We hypothesized that characteristic patterns of Hp gene expression and protein localization in endometrioid adenocarcinoma of the uterus may provide insight into the clinical utility of Hp as a tumor marker or alternative therapeutic approach.
  • METHODS: Biopsies of endometrioid adenocarcinoma tumors of the uterus and their adjacent nonaffected endometrium were collected.
  • Normal endometrium was collected from healthy women.
  • RESULTS: Haptoglobin mRNA levels were significantly greater (P < .005) in endometrioid adenocarcinoma and adjacent nonaffected endometrial tissues than normal endometrium.
  • No correlation was found between Hp levels and cancer stage (P = .673) or grade (P = .739).
  • Haptoglobin protein localized in both stromal and glandular epithelial cells of endometrioid adenocarcinoma and their adjacent nonaffected tissue but not in control endometrium.
  • CONCLUSIONS: Our results have identified, for the first time, unique patterns of Hp mRNA expression and protein localization in the stromal and glandular epithelial cells of endometrioid adenocarcinoma of the uterus.
  • We propose that this unique pattern of endometrioid adenocarcinoma Hp expression may be developed as a novel diagnostic marker.
  • Modulation of Hp, with its immunomodulatory and angiogenic properties, may generate novel methods of prevention or treatment for endometrial cancer.
  • [MeSH-major] Carcinoma, Endometrioid / metabolism. Endometrial Neoplasms / metabolism. Haptoglobins / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19801537.001).
  • [ISSN] 1933-7205
  • [Journal-full-title] Reproductive sciences (Thousand Oaks, Calif.)
  • [ISO-abbreviation] Reprod Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Haptoglobins; 0 / RNA, Messenger
  •  go-up   go-down


48. Barwick TD, Rockall AG, Barton DP, Sohaib SA: Imaging of endometrial adenocarcinoma. Clin Radiol; 2006 Jul;61(7):545-55

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging of endometrial adenocarcinoma.
  • Endometrial cancer is the most common gynaecological malignancy and the incidence rising.
  • This is important as endometrial cancer predominately occurs in postmenopausal women with co-morbidities.
  • Modern imaging provides important tools in the accurate pre-treatment assessment of endometrial cancer and may optimize treatment planning.
  • However, there is little consensus to date on imaging in the routine preoperative assessment of endometrial carcinoma and practice varies amongst many gynaecologists.
  • Transvaginal ultrasound is often the initial imaging examination for women with uterine bleeding.
  • However, once the diagnosis of endometrial cancer has been made, contrast-enhanced magnetic resonance imaging (MRI) provides the best assessment of the disease.
  • The results of contrast-enhanced MRI may identify patients who need more aggressive therapy and referral to a cancer centre.
  • In this article we review the role of imaging in the diagnosis and staging/preoperative assessment of endometrial carcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Endometrial Neoplasms / diagnosis
  • [MeSH-minor] Female. Humans. Lymphatic Metastasis / diagnosis. Lymphatic Metastasis / pathology. Magnetic Resonance Imaging / methods. Magnetic Resonance Imaging / standards. Neoplasm Invasiveness. Neoplasm Staging. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16784939.001).
  • [ISSN] 0009-9260
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 87
  •  go-up   go-down


49. Pervatikar SK, Rao R, Dinesh US: Ossifying luteinized thecoma of the ovary with endometrial adenocarcinoma. Indian J Pathol Microbiol; 2009 Apr-Jun;52(2):222-4
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ossifying luteinized thecoma of the ovary with endometrial adenocarcinoma.
  • We report a case of a 66-year-old post-menopausal female with the chief complaint of uterine bleeding of 7 months duration.
  • Endometrial curettage performed showed features of endometrial adenocarcinoma.
  • This case is the second in the literature of osseous metaplasia in an ovarian luteinized thecoma, with the association of endometrial adenocarcinoma suggesting its functional status.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / diagnosis. Ovarian Neoplasms / pathology. Thecoma / complications. Thecoma / diagnosis. Uterine Neoplasms / pathology
  • [MeSH-minor] Aged. Endometrium / pathology. Female. Humans. Hysterectomy. Luteinization. Ossification, Heterotopic. Ovary / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19332920.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


50. Kilic G, Gurates B, Garon J, Kang H, Arun B, Lampley CE, Kurzel R, Ashfaq R: Expression of cyclooxygenase-2 in endometrial adenocarcinoma. Eur J Gynaecol Oncol; 2005;26(3):271-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cyclooxygenase-2 in endometrial adenocarcinoma.
  • Studies have shown that COX-2 is up-regulated in several epithelial carcinomas.
  • In this study, we wish to elucidate if endometrial cyclooxygenase-2 (COX-2) expression in endometrial adenocarcinoma is increased relative to normal endometrium.
  • Thirty-six deparaffinized tissue sections from patients with endometrial adenocarcinoma were analyzed by immunohistochemistry for the presence of COX-2.
  • A control group consisted of 13 age-matched patients without malignancy, who underwent surgery for uterine prolapse.
  • We found that COX-2 expression was markedly increased in 13 of 36 patients (36.1%) with endometrial adenocarcinoma: in contrast only one of 13 (7.7%) control patients demonstrated increased COX-2 expression (p < or = 0.05).
  • Eight of the 13 COX-2 positive patients in the study had well differentiated adenocarcinoma; the remaining five COX-2 positive patients had moderately and poorly differentiated adenocarcinoma (4 and 1, respectively).
  • In conclusion, COX-2 expression in the endometrium is associated with endometrial adenocarcinoma, especially of the well differentiated type.
  • This may provide an avenue for chemoprevention of endometrial adenocarcinoma.
  • In addition, with new selective inhibitory drugs being developed, inhibition of COX-2 may play an adjunctive role approach to standard therapy, especially for well-differentiated endometrial carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Endometrial Neoplasms / metabolism. Prostaglandin-Endoperoxide Synthases / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15991524.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Proteins; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  •  go-up   go-down


51. Mao Y, Wan X, Chen Y, Lv W, Xie X: Outcomes of conservative therapy for young women with early endometrial adenocarcinoma. Fertil Steril; 2010 Jan;93(1):283-5
MedlinePlus Health Information. consumer health - Assisted Reproductive Technology.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of conservative therapy for young women with early endometrial adenocarcinoma.
  • Four of six patients with endometrial cancer had initial response to progesterone therapy and obtained complete response; three among them had successful pregnancies with three live births.
  • The results suggest that progesterone therapy, combined with assisted reproductive technology, provides more chance of carrying a full-term pregnancy for patients with endometrial adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Endometrial Neoplasms / drug therapy. Fertility / drug effects. Medroxyprogesterone Acetate / therapeutic use. Megestrol Acetate / therapeutic use. Reproductive Techniques, Assisted

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.
  • (PMID = 19962142.001).
  • [ISSN] 1556-5653
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; C2QI4IOI2G / Medroxyprogesterone Acetate; TJ2M0FR8ES / Megestrol Acetate
  •  go-up   go-down


52. Gil da Costa RM, Santos M, Amorim I, Lopes C, Pereira PD, Faustino AM: An immunohistochemical study of feline endometrial adenocarcinoma. J Comp Pathol; 2009 May;140(4):254-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An immunohistochemical study of feline endometrial adenocarcinoma.
  • Feline endometrial adenocarcinomas are uncommon malignant neoplasms that have to date been poorly characterized.
  • The present immunohistochemical study describes the expression of the pancytokeratins AE1 and AE3, cytokeratin-14, vimentin, alpha-actin, cyclo-oxygenase-2, E-cadherin, beta-catenin, the progesterone receptor, the oestrogen receptor and caveolin-1 within normal feline uterine tissue and tissue from six cats with endometrial adenocarcinoma.
  • Synthesis of cyclo-oxygenase-2 and reduced expression of progesterone receptors may be involved in the neoplastic transformation of feline endometrium.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / veterinary. Cat Diseases / metabolism. Endometrial Neoplasms / metabolism. Endometrial Neoplasms / veterinary. Immunohistochemistry / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19201419.001).
  • [ISSN] 1532-3129
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


53. Goldman NA, Katz EB, Glenn AS, Weldon RH, Jones JG, Lynch U, Fezzari MJ, Runowicz CD, Goldberg GL, Charron MJ: GLUT1 and GLUT8 in endometrium and endometrial adenocarcinoma. Mod Pathol; 2006 Nov;19(11):1429-36
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GLUT1 and GLUT8 in endometrium and endometrial adenocarcinoma.
  • Regulation of glucose transport facilitator expression has been demonstrated in endometrial tissue and endometrial adenocarcinoma.
  • The following experiments were conducted to quantify and localize the expression of GLUT1 and GLUT8 in benign endometrium and compare this expression to endometrial cancer.
  • Endometrial tissue samples were obtained from random hysterectomy specimens of patients with benign indications for surgery and endometrial cancer.
  • Endometrial samples from 65 women who had undergone hysterectomy were examined (n=38 benign, n=27 malignant).
  • A 44 and a 35.4 kDa immunoreacive species was demonstrated in endometrium and endometrial cancer for GLUT1 and GLUT8, respectively.
  • GLUT8 expression was increased in all tumor subtypes compared to atrophic endometrium (P<0.001).
  • Apical localization by GLUT1 and GLUT8 was demonstrated in endometrial glands.
  • GLUT1 and GLUT8 demonstrated diffuse intracellular localization in the cancer subtypes.
  • GLUT1 and GLUT8 are expressed in both human endometrium and endometrial cancer.
  • [MeSH-major] Adenocarcinoma / chemistry. Biomarkers, Tumor / analysis. Endometrial Neoplasms / chemistry. Endometrium / chemistry. Glucose Transport Proteins, Facilitative / analysis. Glucose Transporter Type 1 / analysis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16892013.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK47425; United States / NHLBI NIH HHS / HL / HL58119
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glucose Transport Proteins, Facilitative; 0 / Glucose Transporter Type 1; 0 / SLC2A1 protein, human; 0 / SLC2A8 protein, human
  •  go-up   go-down


54. Chen L, Nordlander C, Behboudi A, Olsson B, Levan KK: Deriving evolutionary tree models of the oncogenesis of endometrial adenocarcinoma. Int J Cancer; 2007 Jan 15;120(2):292-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deriving evolutionary tree models of the oncogenesis of endometrial adenocarcinoma.
  • Endometrial adenocarcinoma (EAC) is the fourth leading cause of cancer death in women worldwide, but not much is known about the underlying genetic factors involved in the development of this complex disease.
  • [MeSH-major] Adenocarcinoma / genetics. Allelic Imbalance. Endometrial Neoplasms / genetics. Evolution, Molecular. Models, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 17066454.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


55. Qin Y, Peng Z, Gao Y: Bilateral femur metastasis in endometrial adenocarcinoma. Saudi Med J; 2008 May;29(5):766-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral femur metastasis in endometrial adenocarcinoma.
  • Bone metastasis of endometrial carcinoma is uncommon, and bilateral femur metastasis is extremely rare.
  • A 48-year-old woman with Federation International of Gynecology and Obstetrics stage IIB grade 2-3 endometrial adenocarcinoma underwent curative radical hysterectomy, bilateral salpingo-oophorectomy, and pelvic and para-aortic lymphadenectomy followed by radiotherapy and chemotherapy.
  • Three and a half years after treatment of bony metastasis, she remains clinically well.
  • Bone metastasis of endometrial carcinoma may occur at some unusual sites, and bilateral femur metastasis should be considered in patients.
  • Multimodal therapies are usually advocated for bone metastasis of endometrial carcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Endometrial Neoplasms / pathology. Femoral Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18454230.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Saudi Arabia
  • [Number-of-references] 10
  •  go-up   go-down


56. Tantbirojn P, Triratanachat S, Trivijitsilp P, Niruthisard S: Detection of PTEN immunoreactivity in endometrial hyperplasia and adenocarcinoma. J Med Assoc Thai; 2008 Aug;91(8):1161-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of PTEN immunoreactivity in endometrial hyperplasia and adenocarcinoma.
  • OBJECTIVE: To investigate PTEN (phosphatase and tensin homolog deleted on chromosome 10) expression in endometrial hyperplasia and adenocarcinoma as analyzed by immunohistochemistry.
  • MATERIAL AND METHOD: PTEN protein expression was evaluated by immunohistrochemical study of 70 paraffin-embedded curettage endometrial tissue samples (10 normal endometrium, 55 endometrial hyperplasia, and 15 endometrial adenocarcinomas) selected from surgical pathology files of the Division of Gynecologic Pathology, Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University, from 2001 to 2004.
  • RESULTS: Absence of PTEN protein expression was detected in 60% of endometrial carcinoma, 60% of atypical endometrial hyperplasia, and 24% of typical endometrial hyperplasia.
  • In endometrial hyperplasia without atypia group, the majority of cases revealed moderate to strong PTEN expression, with 70% in simple hyperplasia and 47% in complex hyperplasia.
  • There is a significant statistical difference of PTEN immunoreactivity among proliferative endometrium, endometrial hyperplasia and endometrial carcinoma group (p = 0.004).
  • CONCLUSION: Complete loss of PTEN protein expression was most commonly found in endometrial carcinoma and hyperplasia with cytologic atypia.
  • [MeSH-major] Chromosomes, Human, Pair 10 / genetics. Endometrial Hyperplasia / pathology. Endometrial Neoplasms / diagnosis. Endometrium / cytology. PTEN Phosphohydrolase / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18788685.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


57. Li HW, Leung SW, Chan CS, Yu MM, Wong YF: Expression of maspin in endometrioid adenocarcinoma of endometrium. Oncol Rep; 2007 Feb;17(2):393-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of maspin in endometrioid adenocarcinoma of endometrium.
  • Underexpression of maspin has been reported in breast and prostatic cancers, but in some cancers such as ovarian, colorectal and pancreatic carcinoma, it was found to be up-regulated.
  • This study aimed at demonstrating the expression of maspin in human endometrial tissue and searching for any altered expression in endometrioid adenocarcinoma of the endometrium compared to normal endometrium.
  • The expression level of the maspin gene was studied using reverse transcriptase-polymerase chain reaction (RT-PCR) performed on RNA extracted from 34 endometrial cancer samples (including 24 with FIGO stage I disease and 10 with FIGO stage III disease) and 28 normal endometrium in proliferative or secretory phases.
  • Immunohistochemical staining was also performed on 10 cases of endometrial cancer (6 FIGO stage I cases and 4 FIGO stage III cases) as well as 15 normal endometrium.
  • Semi-quantitative RT-PCR revealed that the expression of maspin was significantly up-regulated in both stage I (p<0.01) and stage III (p<0.01) endometrial cancer compared with normal endometrium.
  • However, no significant difference in maspin expression was demonstrated between stage I and stage III endometrial cancer.
  • Immunostaining of all tissue sections revealed an immunopositive signal in the nuclei of the normal or cancerous endometrial glandular cells.
  • In 60% of the cancer cases, cytoplasmic staining was also evident.
  • Our results suggested that there is up-regulated expression of maspin in endometrioid endometrial adenocarcinoma.
  • Cytoplasmic immuno-expression of maspin is common in endometrial cancer.
  • It may play a role in the malignant transformation of human endometrial tissue.
  • [MeSH-major] Carcinoma, Endometrioid / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Gene Expression Regulation, Neoplastic. Serpins / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17203179.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA Primers; 0 / SERPIN-B5; 0 / Serpins
  •  go-up   go-down


58. Colling R, Lopes T, Das N, Mathew J: Endometrial metastasis of colorectal cancer with coincident endometrial adenocarcinoma. BMJ Case Rep; 2010;2010
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial metastasis of colorectal cancer with coincident endometrial adenocarcinoma.
  • Metastasis to the uterine corpus is uncommon and secondary colorectal tumours of the endometrium are rare.
  • We describe a uterine tumour with components of both primary endometrial and metastatic colorectal carcinomata.
  • She had an abdominoperineal resection 3 years previously for a Dukes stage B rectal carcinoma.
  • A transvaginal ultrasonography showed a thickened endometrium.
  • Histology immunophenotyping showed a CK7+, CK20+, CA125- and CEA+ colorectal metastasis (a profile consistent with her previous cancer) associated with a primary CK7+, CK20-, CA125+ and CEA- endometroid endometrial adenocarcinoma.
  • We conclude this represents endometrial metastasis of colorectal carcinoma with coincident primary endometrial adenocarcinoma.
  • We speculate as to whether the endometrial carcinoma arose de novo or was induced by the colorectal metastasis, or whether the primary endometrial tumour provided a fertile site for the colorectal metastasis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Carcinoma, Endometrioid / diagnosis. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / pathology. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / secondary. Neoplasms, Multiple Primary / diagnosis
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Diagnosis, Differential. Endometrium / pathology. Endosonography. Female. Humans. Image Interpretation, Computer-Assisted. Magnetic Resonance Imaging. Neoplasm Staging. Postoperative Complications / diagnosis. Postoperative Complications / pathology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2000 Apr;13(4):379-88 [10786803.001]
  • [Cites] Eur J Gynaecol Oncol. 2001;22(2):122-6 [11446475.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jan;21(1):11-5 [11781517.001]
  • [Cites] J Natl Cancer Inst. 2004 Feb 18;96(4):261-8 [14970275.001]
  • [Cites] Gynecol Oncol. 2004 Apr;93(1):252-6 [15047246.001]
  • [Cites] Cancer. 1982 Nov 15;50(10):2163-9 [7127256.001]
  • [Cites] Jpn J Surg. 1991 May;21(3):352-6 [1857041.001]
  • [Cites] Pathologe. 1993 Jan;14(1):58-60 [8451231.001]
  • [Cites] Tumori. 1995 Sep-Oct;81(5):383-6 [8804459.001]
  • [Cites] Hepatogastroenterology. 1999 Mar-Apr;46(26):981-2 [10370650.001]
  • [Cites] Dis Esophagus. 2005;18(2):124-6 [16053489.001]
  • [Cites] Int J Gynecol Pathol. 2006 Apr;25(2):101-20 [16633059.001]
  • [Cites] Surg Today. 2008;38(7):651-5 [18612793.001]
  • [Cites] APMIS. 2008 Jun;116(6):538-40 [18754330.001]
  • [Cites] Int J Surg Pathol. 2011 Dec;19(6):787-90 [19443868.001]
  • (PMID = 22791861.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC3028565
  •  go-up   go-down


59. Yahata T, Fujita K, Aoki Y, Tanaka K: Long-term conservative therapy for endometrial adenocarcinoma in young women. Hum Reprod; 2006 Apr;21(4):1070-5
Hazardous Substances Data Bank. MEDROXYPROGESTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term conservative therapy for endometrial adenocarcinoma in young women.
  • BACKGROUND: To evaluate the efficacy and safety of long-term conservative therapy with medroxyprogesterone acetate (MPA) for endometrial carcinoma in young patients who had experienced failure after initial therapy or relapse, we reviewed the clinical and pathologic records of eight patients diagnosed with well-differentiated endometrial adenocarcinoma without myometrial invasion who were treated with MPA for over 6 months because of treatment failure or relapse.
  • All presented well-differentiated endometrioid adenocarcinomas without extrauterine disease.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Endometrial Neoplasms / drug therapy. Medroxyprogesterone / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16361282.001).
  • [ISSN] 0268-1161
  • [Journal-full-title] Human reproduction (Oxford, England)
  • [ISO-abbreviation] Hum. Reprod.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; HSU1C9YRES / Medroxyprogesterone
  •  go-up   go-down


60. Trimble CL, Kauderer J, Zaino R, Silverberg S, Lim PC, Burke JJ 2nd, Alberts D, Curtin J: Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer; 2006 Feb 15;106(4):812-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study.
  • BACKGROUND: Adenocarcinoma of the endometrium is the most common gynecologic malignancy in the United States, accounting for approximately 36,000 diagnoses of invasive carcinoma annually.
  • The most common histologic type, endometrioid adenocarcinoma (EC), accounts for 75-80% of patients.
  • The objective of this work was to estimate the prevalence of concurrent carcinoma in women with a biopsy diagnosis of the precursor lesion, atypical endometrial hyperplasia (AEH).
  • METHODS: This prospective cohort study included women who had a community diagnosis of AEH.
  • Of these, 17 women were not included in the analysis: Two patients had unreadable slides because of poor processing or insufficient tissue, 2 patients had only slides that were not endometrial, the slides for 5 patients were not available for review, and 8 of the hysterectomy specimens were excluded because they showed evidence of interval intervention, either progestin effect or ablation.
  • The study panel review of the AEH biopsy specimens was interpreted as follows: 74 of 289 specimens (25.6%) were diagnosed as less than AEH, 115 of 289 specimens (39.8%) were diagnosed as AEH, and 84 of 289 specimens (29.1%) were diagnosed as endometrial carcinoma.
  • In 5.5% (16 of 289 specimens), there was no consensus on the biopsy diagnosis.
  • The rate of concurrent endometrial carcinoma for analyzed specimens was 42.6% (123 of 289 specimens).
  • Among the women who had hysterectomy specimens with carcinoma, 14 of 74 women (18.9%) had a study panel biopsy consensus diagnosis of less than AEH, 45 of 115 women (39.1%) had a study panel biopsy consensus diagnosis of AEH, and 54 of 84 women (64.3%) had a study panel diagnosis of carcinoma.
  • Among women who had no consensus in their biopsy diagnosis, 10 of 16 women (62.5%) had carcinoma in their hysterectomy specimens.
  • CONCLUSIONS: The prevalence of endometrial carcinoma in patients who had a community hospital biopsy diagnosis of AEH was high (42.6%).
  • When considering management strategies for women who have a biopsy diagnosis of AEH, clinicians and patients should take into account the considerable rate of concurrent carcinoma.
  • [MeSH-major] Adenocarcinoma / epidemiology. Endometrial Hyperplasia / complications. Endometrial Hyperplasia / pathology. Endometrial Neoplasms / epidemiology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • [CommentIn] Cancer. 2006 Feb 15;106(4):729-31 [16400641.001]
  • (PMID = 16400639.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


61. Takacs P, De Santis T, Nicholas MC, Verma U, Strassberg R, Duthely L: Echogenic endometrial fluid collection in postmenopausal women is a significant risk factor for disease. J Ultrasound Med; 2005 Nov;24(11):1477-81
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Echogenic endometrial fluid collection in postmenopausal women is a significant risk factor for disease.
  • OBJECTIVE: The purpose of this study was to assess postmenopausal women with endometrial fluid collection and the risk of significant endometrial or cervical disease.
  • METHODS: A retrospective chart review was conducted of 343 postmenopausal women with endometrial fluid collection on pelvic sonography.
  • Medical records were reviewed to identify women who underwent an evaluation of the endometrium with endometrial biopsy, hysteroscopy, or hysterectomy after the sonographic examination.
  • Clinical and sonographic characteristics were compared between women with diagnoses of cervical or endometrial cancer or hyperplasia (nonbenign group) and women with benign conditions (benign group).
  • RESULTS: The endometrium was significantly thicker in the nonbenign group compared with the benign group (mean +/- SD, 9.9 +/- 7.4 versus 5.9 +/- 4.1 mm; P = .016).
  • None of the patients with adenocarcinoma of the endometrium had endometrial thickness of 3 mm or less, but 2 with endocervical cancer did.
  • Echogenic fluid in the endometrial cavity was significantly more likely to be found in the nonbenign group compared with the benign group (45.8% versus 4.8%; P < .01).
  • Multivariate logistic regression analysis revealed that echogenic fluid in the endometrial cavity was the only significant risk factor for nonbenign conditions (odds ratio, 10.94; 95% confidence interval, 2.67-44.84; P < .01).
  • CONCLUSIONS: Postmenopausal women with endometrial fluid collection on sonography should undergo endometrial sampling if the endometrial lining is thicker than 3 mm or the endometrial fluid is echogenic.
  • If the lining is 3 mm or less and the endometrial fluid is clear, endometrial sampling is not necessary, but we recommend endocervical sampling to rule out endocervical cancer.
  • [MeSH-major] Endometrium. Postmenopause. Uterine Cervical Diseases / ultrasonography
  • [MeSH-minor] Body Fluids. Female. Humans. Middle Aged. Retrospective Studies. Risk Factors. Uterine Diseases / ultrasonography

  • MedlinePlus Health Information. consumer health - Cervix Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16239648.001).
  • [ISSN] 0278-4297
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Wilson M, Hermes R, Bainbridge J, Bassett H: A case of metastatic uterine adenocarcinoma in a southern white rhinoceros (Ceratotherium simum simum). J Zoo Wildl Med; 2010 Mar;41(1):111-4
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of metastatic uterine adenocarcinoma in a southern white rhinoceros (Ceratotherium simum simum).
  • The rhinoceros' uterus had previously been evaluated by ultrasound and diffuse endometrial hyperplasia and two benign uterine leiomyomas had been diagnosed.
  • At necropsy examination, a large, infiltrative, metastatic uterine adenocarcinoma was found multifocally throughout the uterus, scattered within the peritoneal cavity, on the diaphragm, the splenic capsule, the pleural surface of the lung and mesenteric lymph nodes.
  • [MeSH-major] Adenocarcinoma / veterinary. Lung Neoplasms / veterinary. Perissodactyla. Peritoneal Neoplasms / veterinary. Splenic Neoplasms / veterinary. Uterine Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20722262.001).
  • [ISSN] 1042-7260
  • [Journal-full-title] Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians
  • [ISO-abbreviation] J. Zoo Wildl. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Mittal K, Sebenik M, Irwin C, Yan Z, Popiolek D, Curtin J, Palazzo J: Presence of endometrial adenocarcinoma in situ in complex atypical endometrial hyperplasia is associated with increased incidence of endometrial carcinoma in subsequent hysterectomy. Mod Pathol; 2009 Jan;22(1):37-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presence of endometrial adenocarcinoma in situ in complex atypical endometrial hyperplasia is associated with increased incidence of endometrial carcinoma in subsequent hysterectomy.
  • The distinction of complex atypical endometrial hyperplasia from endometrial adenocarcinoma is often problematic.
  • Foci of back-to-back arrangement of glands or foci of cribriform arrangement of glands smaller than 2.1 mm in diameter are considered insufficient for the diagnosis of endometrial adenocarcinoma by some authors, and sufficient to be diagnosed as endometrial adenocarcinoma by other authors.
  • We refer to these foci as endometrial adenocarcinoma in situ.
  • In this study, we evaluated findings in subsequent hysterectomy in complex atypical endometrial hyperplasia patients with and without adenocarcinoma in situ.
  • Follow-up findings, including the presence or absence of endometrial adenocarcinoma in the hysterectomy specimen, the grade of the carcinoma and the depth of myometrial invasion were analyzed.
  • Of the total 87 patients with complex atypical endometrial hyperplasia, 33 patients had adenocarcinoma in situ and 54 lacked adenocarcinoma in situ.
  • Of 33 patients 22 (66%) with adenocarcinoma in situ had endometrial adenocarcinoma on subsequent hysterectomy vs 13 of 54 (24%) patients without adenocarcinoma in situ (P=0.0001).
  • Myoinvasive endometrial adenocarcinoma was present in 20 of 33 (61%) patients with adenocarcinoma in situ vs 8 of the 54 (15%) patients without adenocarcinoma in situ (P< or =0.0001).
  • The depth of myometrial invasion in cases with myoinvasion was 24.5+19.4% in patients with adenocarcinoma in situ and 12.8+8.5% in patients without adenocarcinoma in situ (P=0.05).
  • Among patients younger than age of 50, 5 of the 7 (71%) with adenocarcinoma in situ had myoinvasive carcinoma vs 2 of the 13 (15%) without adenocarcinoma in situ (P=0.02).
  • The likelihood of finding endometrial adenocarcinoma in subsequent hysterectomy in patients with complex atypical endometrial hyperplasia is significantly increased if adenocarcinoma in situ is present in prior endometrial sampling.
  • Endometrial adenocarcinomas in patients with adenocarcinoma in situ are far more frequently myoinvasive, and invade to a greater depth than endometrial adenocarcinomas seen in patients without adenocarcinoma in situ.
  • Use of adenocarcinoma in situ terminology could lead to improved management of patients with complex atypical endometrial hyperplasia.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma in Situ / pathology. Endometrial Hyperplasia / pathology. Endometrial Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19116629.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Areia A, Branco M, Frutuoso C, de Oliveira CF: Endometrial adenocarcinoma after endometrial ablation. A case report. Eur J Gynaecol Oncol; 2006;27(4):432-3
MedlinePlus Health Information. consumer health - Vaginal Bleeding.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial adenocarcinoma after endometrial ablation. A case report.
  • The authors present a case of endometrial adenocarcinoma after endometrial ablation, emphasizing the importance of close surveillance of these patients, patient selection and education.
  • Even patients with none of the risk factors for endometrial cancer or contraindications to endometrial ablation should be checked carefully.
  • [MeSH-major] Adenocarcinoma / diagnosis. Catheter Ablation. Endometrial Neoplasms / diagnosis. Endometrium / pathology. Uterine Hemorrhage / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17009646.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


65. Mylonas I, Makovitzky J, Shabani N, Richter DU, Kuhn C, Jeschke U, Briese V, Friese K: Leukaemia inhibitory factor (LIF) is immunohistochemically expressed in normal, hyperplastic and malignant endometrial tissue. Eur J Obstet Gynecol Reprod Biol; 2005 Jan 10;118(1):101-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukaemia inhibitory factor (LIF) is immunohistochemically expressed in normal, hyperplastic and malignant endometrial tissue.
  • Therefore, the aim of this study was to determine the frequency and tissue distribution of LIF in normal, hyperplastic and malignant endometrium.
  • STUDY DESIGN: Paraffin-fixed endometrial tissue was obtained from normal premenopausal women (n = 15), endometrial hyperplasia (n = 20), endometroid adenocarcinoma (n = 32) and endometrial polyps (n = 9).
  • RESULTS: The lowest expression of LIF was observed in endometrial adenocarcinomas compared to all groups, while endometrial polyps expressed the highest LIF immunostaining.
  • The highest expression of LIF was observed in endometrial polyps.
  • Simple hyperplasia showed a significantly higher LIF expression than proliferative endometrium and adenocarcinoma.
  • Adenomatous hyperplasia (AH) grade I-III had a significantly higher LIF expression than adenocarcinoma.
  • The lowest expression of LIF was observed in adenocarcinoma, being statistically significant compared to all groups.
  • CONCLUSION: LIF was immunohistochemically demonstrated in normal, hyperplastic and malignant endometrial tissue, suggesting a widespread but complex role for LIF in hyperplastic and malignant endometrial growth regulation.
  • AH I-III also expressed LIF with statistically higher immunostaining than adenocarcinoma.
  • Since AH III can be considered as a precursor of endometrial cancer, LIF could be a marker of cell transformation.
  • [MeSH-major] Endometrial Hyperplasia / metabolism. Endometrial Neoplasms / chemistry. Endometrium / chemistry. Immunohistochemistry. Interleukin-6 / analysis
  • [MeSH-minor] Adenocarcinoma / chemistry. Female. Humans. Leukemia Inhibitory Factor. Polyps / chemistry. Premenopause

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15596282.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Interleukin-6; 0 / LIF protein, human; 0 / Leukemia Inhibitory Factor
  •  go-up   go-down


66. Liu WK, Jiang XY, Zhang ZX: Expression of PSCA, PIWIL1, and TBX2 in endometrial adenocarcinoma. Onkologie; 2010;33(5):241-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of PSCA, PIWIL1, and TBX2 in endometrial adenocarcinoma.
  • BACKGROUND: Endometrial cancer is the 4th most common gynecological cancer.
  • The expression of prostate stem cell antigen (PSCA), piwi-like 1 (PIWIL1), and T-box 2 (TBX2) in endometrial cancer remains to be elucidated.
  • MATERIAL AND METHODS: The expression of PSCA, PIWIL1, and TBX2 was examined using the streptavidin-peroxidase method in 64 endometrial endometrioid adenocarcinoma (EAC) and paired normal endometrium (NE) samples from the Shaanxi Province in China.
  • Our findings suggest that PSCA and TBX2 might be candidate targets for cancer therapy, and have helped us further understand the carcinogenesis of endometrial cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Endometrial Neoplasms / genetics. Gene Expression Regulation, Neoplastic / genetics. Membrane Glycoproteins / genetics. Neoplasm Proteins / genetics. Proteins / genetics. T-Box Domain Proteins / genetics
  • [MeSH-minor] Adult. Age Factors. Aged. Antigens, Neoplasm. Argonaute Proteins. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. Endometrium / pathology. Female. GPI-Linked Proteins. Humans. Immunoenzyme Techniques. Lymphatic Metastasis / pathology. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20502058.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Argonaute Proteins; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins; 0 / PIWIL1 protein, human; 0 / PSCA protein, human; 0 / Proteins; 0 / T-Box Domain Proteins; 0 / TBX1 protein, human
  •  go-up   go-down


67. Shutter J, Wright TC Jr: Prevalence of underlying adenocarcinoma in women with atypical endometrial hyperplasia. Int J Gynecol Pathol; 2005 Oct;24(4):313-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of underlying adenocarcinoma in women with atypical endometrial hyperplasia.
  • There is controversy regarding the prevalence of underlying endometrial adenocarcinoma among women with a diagnosis of atypical endometrial hyperplasia.
  • At our institution atypical endometrial proliferations non-diagnostic for invasive adenocarcinoma are diagnosed as either atypical endometrial hyperplasia (ATHY) or as an "atypical proliferative lesion of the endometrium, suggestive but not diagnostic of atypical endometrial hyperplasia" (APL).
  • Between 1996 and 2003, these diagnoses were made on either endometrial biopsy or endometrial curettings in 60 women who subsequently received a hysterectomy.
  • Endometrial adenocarcinoma was identified in 48% (29/60) of the hysterectomy specimens.
  • Age and sampling method had no significant impact on the prevalence of adenocarcinoma.
  • Adenocarcinoma was no more likely to be subsequently identified when a woman had a preoperative diagnosis of ATHY (24 of 52, 46%) compared to APL (5 of 8, 63%).
  • In some women with a diagnosis of ATHY a comment was made in the report that "carcinoma cannot be ruled out".
  • These cases had a significantly higher prevalence of underlying adenocarcinoma (16 of 25, 64%) compared to cases of ATHY in which such a comment was not made (8 of 27, 30%) (p = 0.025).
  • In conclusion, there is a high prevalence of underlying endometrial adenocarcinoma among women undergoing hysterectomy for any of atypical endometrial proliferation.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Hyperplasia / pathology. Endometrial Neoplasms / pathology
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Female. Humans. Hysterectomy. Middle Aged. Neoplasm Staging. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16175074.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Terada T, Kawaguchi M: Primary clear cell adenocarcinoma of the peritoneum. Tohoku J Exp Med; 2005 Jul;206(3):271-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary clear cell adenocarcinoma of the peritoneum.
  • We report on a very rare case of peritoneal clear cell adenocarcinomas.
  • A 49-year-old Japanese woman underwent hysterectomy and bilateral salpingo-oophorectomy for endometrial endometrioid adenocarcinoma grade III, which was composed of undifferentiated carcinoma cells (98%) and tubular carcinoma cells (2%).
  • No clear cell adenocarcinoma elements were noted in this tumor.
  • Two peritoneal cystic tumors were detected by imaging modalities around the stomach and spleen, 15 months and 21 months after the follow-up period of the endometrial carcinoma, respectively.
  • They showed proliferation of carcinoma cells arranged in solid nest, tubular, and papillary patterns.
  • The morphologies fulfilled the criteria of clear cell adenocarcinoma.
  • The morphologies and immunohistochemical findings of the two peritoneal clear cell adenocarcinomas were different from those of endometrial carcinoma.
  • We believe that the two clear cell adenocarcinomas are not metastatic lesions from the endometrial carcinoma of the uterus, and that they are primary clear cell adenocarcinomas of the peritoneum.
  • Our case was characterized by cyst formations and encapsulation in addition to the common histological features of clear cell adenocarcinoma of the uterus and ovary.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Peritoneal Neoplasms / diagnosis
  • [MeSH-minor] Cell Proliferation. Cytoplasm / metabolism. Endometrial Neoplasms / metabolism. Female. Humans. Hysterectomy. Immunohistochemistry. Middle Aged. Ovary / pathology. Periodic Acid-Schiff Reaction. Spleen / metabolism. Stomach / metabolism. Uterine Neoplasms. Uterus / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15942157.001).
  • [ISSN] 0040-8727
  • [Journal-full-title] The Tohoku journal of experimental medicine
  • [ISO-abbreviation] Tohoku J. Exp. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


69. Yang X, Dong Y, Zhao J, Sun H, Deng Y, Fan J, Yan Q: Increased expression of human macrophage metalloelastase (MMP-12) is associated with the invasion of endometrial adenocarcinoma. Pathol Res Pract; 2007;203(7):499-505

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of human macrophage metalloelastase (MMP-12) is associated with the invasion of endometrial adenocarcinoma.
  • To evaluate the association between the expression of human macrophage metalloelastase (matrix metalloproteinase-12, MMP-12) with cancer invasion and differentiation of endometrial adenocarcinoma, specimens from endometrial adenocarcinoma (n=61) of diverse stages and histologic types were collected from patients having undergone hysterectomy, and specimens from normal endometrium (n=38) were obtained from patients with benign diseases.
  • The positive rate of MMP-12 was significantly increased in endometrial adenocarcinoma (81.97%) as compared with that in normal endometrium (13.16%).
  • The results showed that expression of MMP-12 correlated with stage (p=0.022) and grade (p=0.018) of endometrial cancer.
  • MMP-12 immunoreactive proteins were found mainly on the glandular epithelial cells of endometrial adenocarcinoma.
  • The macrophage infiltration detected by CD68 immunohistochemical staining in endometrial adenocarcinoma was also higher than that in normal endometrium.
  • In this study, we show that in addition to macrophages, endometrial adenocarcinoma cells are able to express MMP-12.
  • Increased MMP-12 expression tended to be associated with the extent of adenocarcinoma invasion accompanied by marked macrophage infiltration.
  • Our results suggest that MMP-12 is an important oncogene in high-stage and high-grade endometrial adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Endometrial Neoplasms / metabolism. Matrix Metalloproteinase 12 / biosynthesis. Neoplasm Invasiveness / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17574772.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; EC 3.4.24.65 / Matrix Metalloproteinase 12
  •  go-up   go-down


70. Gao M, Sun P, Wang J, Zhao D, Wei L: Expression of estrogen receptor-related receptor isoforms and clinical significance in endometrial adenocarcinoma. Int J Gynecol Cancer; 2006 Mar-Apr;16(2):827-33

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of estrogen receptor-related receptor isoforms and clinical significance in endometrial adenocarcinoma.
  • The purpose of this study was to explore whether ERRs were involved in the tumorigenesis of endometrial adenocarcinoma.
  • We examined the expression of ERRs in endometrial adenocarcinoma and normal endometrium using semiquantitative reverse transcription-polymerase chain reaction and immunohistochemistry.
  • The expression rate and relative level of ERRalpha mRNA in ERalpha-positive endometrial adenocarcinomas were lower than in normal endometriums (P= 0.049 and P= 0.023), whereas the relative level of ERRgamma mRNA in ERalpha-positive endometrial adenocarcinomas was higher than in normal endometriums (P= 0.014).
  • Results suggested that ERRalpha and ERRgamma might participate in the tumorigenesis of endometrial adenocarcinoma.
  • ERRalpha and ERRgamma are promising to be new prognostic factors in endometrial adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Endometrial Neoplasms / metabolism. Receptors, Cytoplasmic and Nuclear / metabolism. Receptors, Estrogen / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681769.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / ERRalpha estrogen-related receptor; 0 / ESRRB protein, human; 0 / ESRRG protein, human; 0 / RNA, Messenger; 0 / Receptors, Cytoplasmic and Nuclear; 0 / Receptors, Estrogen
  •  go-up   go-down


71. de Góis Speck NM, Focchi J, Alves AC, Ribalta JC, Osório CA: Relationship between angiogenesis and grade of histologic differentiation in endometrial adenocarcinoma. Eur J Gynaecol Oncol; 2005;26(6):599-601

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between angiogenesis and grade of histologic differentiation in endometrial adenocarcinoma.
  • The objective of the study was to quantify vessels and to relate them to the degree of histologic differentiation in endometrial adenocarcinoma.
  • We studied 35 cases of which ten were G1, 13 G2 and 12 G3 adenocarcinomas.
  • Mean vessel count was 15.3 for G1; 19 for G2 and 22.7 for G3 adenocarcinomas; in the control group it was 11.6 for atrophic and 13.2 for proliferative endometria.
  • Slightly differentiated adenocarcinoma presented greater angiogenesis than normal and well-differentiated carcinoma.
  • In contrast, moderately differentiated carcinoma showed greater angiogenicity as related to normal endometrium, but did not differ from other tumoral endometria.
  • [MeSH-major] Carcinoma, Endometrioid / blood supply. Endometrial Neoplasms / blood supply. Endometrium / blood supply. Neovascularization, Pathologic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16398216.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


72. Koistinen H, Seppälä M, Nagy B, Tapper J, Knuutila S, Koistinen R: Glycodelin reduces carcinoma-associated gene expression in endometrial adenocarcinoma cells. Am J Obstet Gynecol; 2005 Dec;193(6):1955-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glycodelin reduces carcinoma-associated gene expression in endometrial adenocarcinoma cells.
  • OBJECTIVE: Glycodelin is a major secretory glycoprotein of differentiated endometrial epithelium, rarely expressed in proliferative endometrium or endometrial cancer.
  • We aimed to elucidate its role in growth and gene expression of endometrial adenocarcinoma cells, and hypothesized that glycodelin affects cell growth and tumor-associated gene expression.
  • STUDY DESIGN: Endometrial adenocarcinoma HEC-1B cells were transfected with glycodelin cDNA in both antisense and sense orientations.
  • RESULTS: Compared with native and antisense-transfected carcinoma cells, sense-transfected, glycodelin-producing carcinoma cells showed reduced proliferation, morphologic changes, and altered expression of cancer-related genes.
  • CONCLUSION: Reduction by glycodelin transfection of carcinoma cell proliferation and expression of MUC1 and Bcl-XL is significant because these genes are often overexpressed in human cancers--MUC1 is linked to invasive growth and metastases, and both confer resistance to chemotherapy.
  • These results suggest a novel mechanism whereby malignant growth of endometrial adenocarcinoma cells is regulated.
  • [MeSH-major] Adenocarcinoma / genetics. Endometrial Neoplasms / genetics. Gene Expression Regulation, Neoplastic / physiology. Glycoproteins / physiology. Pregnancy Proteins / physiology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16325596.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens; 0 / Antigens, Neoplasm; 0 / Antisense Elements (Genetics); 0 / Glycoproteins; 0 / MUC1 protein, human; 0 / Mucin-1; 0 / Mucins; 0 / PAEP protein, human; 0 / Pregnancy Proteins; 0 / bcl-X Protein
  •  go-up   go-down


73. Sesti F, Patrizi L, Ermini B, Palmieri G, Orlandi A, Piccione E: High-grade endometrial stromal sarcoma after tamoxifen therapy for breast cancer. Gynecol Obstet Invest; 2005;60(2):117-20
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-grade endometrial stromal sarcoma after tamoxifen therapy for breast cancer.
  • A case of high-grade endometrial stromal sarcoma, confined into an intrauterine polypoid growth, in a woman with a history of breast cancer who was treated with adjuvant tamoxifen.
  • Based on the findings, a high-grade endometrial stromal sarcoma was diagnosed.
  • Pathological examination on multiple uterine sections showed the absence of residual tumor cells in the uterus.
  • The endometrium showed patterns of glandular cystic hyperplasia.
  • In deciding if tamoxifen therapy is warranted, all potentially life-threatening adverse events associated with tamoxifen should be considered, including endometrial adenocarcinoma or uterine sarcoma.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Neoplasms, Second Primary / chemically induced. Sarcoma, Endometrial Stromal / chemically induced. Tamoxifen / adverse effects. Uterine Neoplasms / chemically induced


74. Kato S, Espinoza N, Lange S, Villalón M, Cuello M, Owen GI: Characterization and phenotypic variation with passage number of cultured human endometrial adenocarcinoma cells. Tissue Cell; 2008 Apr;40(2):95-102

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization and phenotypic variation with passage number of cultured human endometrial adenocarcinoma cells.
  • Despite numerous endometrial cancer cell lines, little is know about the progression and transition of primary cultured endometrial tumours.
  • Herein, a stage I grade III endometrial adenocarcinoma was maintained in primary culture and the phenotypic and protein expression changes were observed in relation to passage number.
  • At early passage numbers, cultured human endometrial cancer (CHEC) cells displayed classic epithelial cell morphology, growing in groups in a glandular structure and staining positive for cytokeratin.
  • We further characterised CHEC cells through a screening of cancer related proteins, among others, caveolin-1 and Tissue factor in comparison with established cancer cell lines and corresponding non-cancerous cells.
  • This report demonstrates that endometrial adenocarcinoma cells in culture can undergo phenotypic and protein expression changes reminiscent of epithelial-mesenchymal transition.
  • This work suggests that primary tumours and cell lines displaying stromal morphologies may have undergone epithelial-mesenchymal transition from an adenocarcinoma origin.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18031781.001).
  • [ISSN] 0040-8166
  • [Journal-full-title] Tissue & cell
  • [ISO-abbreviation] Tissue Cell
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / / GR071469
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Cytoskeletal Proteins
  •  go-up   go-down


75. Tanaka H, Sato H, Konishi Y, Fujimoto T, Takahashi O, Tanaka T: Endometrial adenocarcinoma after liver transplantation. J Obstet Gynaecol Res; 2005 Jun;31(3):224-6
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial adenocarcinoma after liver transplantation.
  • In December 2001, the patient was found to suffer from endometrial adenocarcinoma and total abdominal hysterectomy with adnexa was carried out.
  • The present case is the first report of endometrial adenocarcinoma in a patient after liver transplantation.
  • [MeSH-major] Adenocarcinoma / diagnosis. Endometrial Neoplasms / diagnosis. Liver Transplantation
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15916658.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


76. Uchida H, Maruyama T, Nagashima T, Asada H, Yoshimura Y: Histone deacetylase inhibitors induce differentiation of human endometrial adenocarcinoma cells through up-regulation of glycodelin. Endocrinology; 2005 Dec;146(12):5365-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histone deacetylase inhibitors induce differentiation of human endometrial adenocarcinoma cells through up-regulation of glycodelin.
  • In human endometrium, postovulatory production of progesterone directs estrogen-primed endometrial glandular cells to differentiate and thereby produce a number of unique bioactive substances, including glycodelin, that are critical for implantation at the secretory phase of the menstrual cycle.
  • In this study, we show that TSA and SAHA, belonging to the hydroxamic acid group of HDACIs, can induce the phenotype of a human endometrial adenocarcinoma cell line, Ishikawa (originally derived from the glandular component of the endometrium), to differentiate to closely resemble normal endometrial epithelium in a time- and dose-dependent manner, as determined by morphological changes, synthesis of glycogen, and expression of secretory phase-specific proteins, including glycodelin.
  • Furthermore, the gene silencing of glycodelin by small interference RNA resulted in the blockade of HDACI-induced differentiation in Ishikawa cells, suggesting the requirement for glycodelin for endometrial epithelial differentiation.
  • Our results collectively indicate that TSA and SAHA are potent differentiation inducers for endometrial glandular cells, providing a clue for a possible therapeutic strategy to modulate endometrial function by targeting glycodelin.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Endometrial Neoplasms / metabolism. Endometrial Neoplasms / pathology. Enzyme Inhibitors / pharmacology. Glycoproteins / metabolism. Histone Deacetylase Inhibitors. Pregnancy Proteins / metabolism

  • Hazardous Substances Data Bank. Vorinostat .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. PROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16123169.001).
  • [ISSN] 0013-7227
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Glycoproteins; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 0 / Interleukin-6; 0 / LIF protein, human; 0 / Leukemia Inhibitory Factor; 0 / PAEP protein, human; 0 / Pregnancy Proteins; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 3X2S926L3Z / trichostatin A; 4G7DS2Q64Y / Progesterone; 4TI98Z838E / Estradiol; 58IFB293JI / vorinostat; 9005-79-2 / Glycogen
  •  go-up   go-down


77. DeBernardo RL, Littell RD, Luo H, Duska LR, Oliva E, Kirley SD, Lynch MP, Zukerberg LR, Rueda BR: Defining the extent of cables loss in endometrial cancer subtypes and its effectiveness as an inhibitor of cell proliferation in malignant endometrial cells in vitro and in vivo. Cancer Biol Ther; 2005 Jan;4(1):103-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Defining the extent of cables loss in endometrial cancer subtypes and its effectiveness as an inhibitor of cell proliferation in malignant endometrial cells in vitro and in vivo.
  • Loss of Cables expression is associated with a high incidence of endometrial hyperplasia and endometrial adenocarcinoma in humans.
  • The Cables mutant mouse develops endometrial hyperplasia and following exposure to chronic estrogen develops early endometrial adenocarcinoma.
  • (1) loss of Cables expression occurred in high grade endometrioid adenocarcinoma, uterine serous and clear cell carcinoma as observed in endometrial hyperplasia and low grade endometrial adenocarcinoma;.
  • (2) overexpression of Cables inhibited cell proliferation in endometrial cancer (EC) cells in vitro and in vivo; and (3) progesterone could regulate the expression of Cables mRNA.
  • Hyperplastic endometrium and low and high grade endometrioid adenocarcinoma showed loss of Cables expression when compared to benign control secretory endometrium.
  • Loss of Cables expression in serous and clear cell tumors was similar to that observed in endometrioid adenocarcinomas with greater than 80% showing loss of protein expression.
  • The progesterone-induced increase in cables was abrogated in the presence of a progesterone receptor (PR) antagonist, suggesting the PR mediates the increase.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / pathology. Cell Proliferation. Endometrial Neoplasms / genetics. Endometrial Neoplasms / pathology. Gene Expression Profiling

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15662117.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA98333
  • [Publication-type] Clinical Conference; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CABLES1 protein, human; 0 / Carrier Proteins; 0 / Cyclins; 0 / Phosphoproteins; 0 / Receptors, Progesterone
  •  go-up   go-down


78. Karna E, Palka JA: Mechanism of betulinic acid inhibition of collagen biosynthesis in human endometrial adenocarcinoma cells. Neoplasma; 2009;56(4):361-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mechanism of betulinic acid inhibition of collagen biosynthesis in human endometrial adenocarcinoma cells.
  • Since betulinic acid (BA) evokes anticancer activity, its effect on collagen biosynthesis was studied in cultured endometrial adenocarcinoma cells.
  • The data suggest that BA-dependent inhibition of collagen biosynthesis in cultured human endometrial adenocarcinoma cells undergoes through alpha2 integrin and IGF-IR signaling that activate NF-kappaB, potent inhibitor of collagen gene expression.
  • [MeSH-major] Adenocarcinoma / metabolism. Antineoplastic Agents, Phytogenic / pharmacology. Collagen / antagonists & inhibitors. Endometrial Neoplasms / metabolism. Signal Transduction / drug effects. Triterpenes / pharmacology

  • Hazardous Substances Data Bank. (L)-PROLINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19469659.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Integrin alpha2beta1; 0 / NF-kappa B; 0 / Son of Sevenless Proteins; 0 / Triterpenes; 4G6A18707N / betulinic acid; 9007-34-5 / Collagen; 9DLQ4CIU6V / Proline; EC 2.7.10.1 / Receptor, IGF Type 1; EC 2.7.10.2 / Focal Adhesion Protein-Tyrosine Kinases; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  •  go-up   go-down


79. Kogan EA, Niziaeva NV, Demura TA, Ezhova LS, Unanian AL: [The morphological and immunohiochemical features of foci of adenomyosis: in its concurrence with endometrial adenocarcinoma]. Arkh Patol; 2010 Jul-Aug;72(4):7-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The morphological and immunohiochemical features of foci of adenomyosis: in its concurrence with endometrial adenocarcinoma].
  • The purpose of the investigation was to study the morphological variants and molecular changes of the endothelial component of adenomyosis (AM) concurrent with endometrial adenocarcinoma (EAC).
  • The foci of AM, which corresponded to epithelial hyperplasia with atypia, were characterized by the oncomarker changes supporting its malignant potential: elevated Ki-67 and EGRF, reduced E-cadherin, changes in MMP-2, MMP-9, TIMP-1, and claudins-2, -3, and -5.
  • [MeSH-major] Adenocarcinoma. Endometrial Neoplasms. Endometriosis. Gene Expression Regulation, Neoplastic. Neoplasm Proteins / biosynthesis


80. Saito M, Sato Y, Watanabe J, Kuramoto H, Kaba S, Fukuda T: Angiogenic factors in normal endometrium and endometrial adenocarcinoma. Pathol Int; 2007 Mar;57(3):140-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiogenic factors in normal endometrium and endometrial adenocarcinoma.
  • In the endometrium, angiogenesis plays important roles not only in tumor growth but also in the menstrual cycle.
  • The purpose of the present paper was to investigate immunohistochemically the correlation between angiogenic factor expression and angiogenic score in normal and neoplastic endometrium.
  • Immunohistochemical staining for vascular endothelial growth factor (VEGF), angiopoietin (Ang)-1, Ang2, Tie2, CD34 and CD105 was performed on formalin-fixed and paraffin-embedded tissues from 31 normal endometrium and 85 endometrial adenocarcinoma.
  • The levels of each angiogenic factor were different in the phases of the menstrual cycle and each layer of normal endometrium.
  • In general, VEGF and Tie2 expression was higher in adenocarcinoma than in normal epithelial cells.
  • Conversely, Ang1 and Ang2 expression was higher in normal epithelium than in adenocarcinoma.
  • The angiogenic score (CD105/CD34) tended to be higher in the adenocarcinoma than in the normal epithelium.
  • It is suggested that the angiogenic pathway and the role of these factors seem to differ between normal tissue and carcinoma of the endometrium.
  • [MeSH-major] Adenocarcinoma / metabolism. Angiogenesis Inducing Agents / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17295646.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / ANGPT1 protein, human; 0 / Angiogenesis Inducing Agents; 0 / Angiopoietin-1; 0 / Angiopoietin-2; 0 / Antigens, CD; 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / ENG protein, human; 0 / Receptors, Cell Surface; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptor, TIE-2
  •  go-up   go-down


81. Li ZL, Morishima S, Tang JT, Otsuki Y: Apoptotic effects of Tian-Long compound on endometrial adenocarcinoma cells in vitro. Med Mol Morphol; 2009 Mar;42(1):32-9
Hazardous Substances Data Bank. ESTRADIOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoptotic effects of Tian-Long compound on endometrial adenocarcinoma cells in vitro.
  • To explore its antitumor properties and the mechanism for activity in gynecological malignancies, the present studies were carried out using Ishikawa cells derived from uterine endometrial adenocarcinoma.
  • The present results indicate that the ingredients of TL compound are very promising for use in the treatment of endometrial adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / pharmacology. Apoptosis / drug effects. Drugs, Chinese Herbal / pharmacology. Endometrial Neoplasms / drug therapy. Phytotherapy

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19294490.001).
  • [ISSN] 1860-1480
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / DNA, Neoplasm; 0 / Drugs, Chinese Herbal; 0 / Phosphatidylserines; 0 / Proto-Oncogene Proteins c-bcl-2; 4TI98Z838E / Estradiol; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / CASP9 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 9
  •  go-up   go-down


82. Novac L, Grigore T, Cernea N, Niculescu M, Cotarcea S: Incidence of endometrial carcinoma in patients with endometrial hyperplasia. Eur J Gynaecol Oncol; 2005;26(5):561-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of endometrial carcinoma in patients with endometrial hyperplasia.
  • OBJECTIVE: The purpose of this retrospective study was to establish the risk of developing endometrial adenocarcinoma in patients diagnosed with endometrial hyperplasia.
  • MATERIAL AND METHODS: The incidence of endometrial hyperplasia and its relation with endometrial adenocarcinoma was evaluated in 1,139 patients who presented with abnormal bleeding between January 2000 and December 2004; D&C was performed in all cases.
  • There were 591 (51.88%) cases of simple endometrial hyperplasia, out of which 110 (18.61% from 51.88%) cases had atypia, 60 (5.26%) cases of complex hyperplasia, out of which 19 (31.66% from 5.26%) had atypia, and the remaining 488 (42.84%) had different forms of mixed hyperplasia.
  • RESULTS: The incidence of endometrial adenocarcinoma was 3.87% in atypical hyperplasia and 0.81% in other forms, and was related only to cases with atypia in which the incidence was 0.61%.
  • CONCLUSIONS: The most indicated measure to prevent endometrial carcinoma in cases with complex endometria hyperplasia with atypia is hysterectomy, while for other forms of hyperplasia, hormonal treatment is used but only under strict control.
  • [MeSH-major] Adenocarcinoma / epidemiology. Endometrial Neoplasms / epidemiology
  • [MeSH-minor] Adult. Age Distribution. Endometrial Hyperplasia / epidemiology. Endometrial Hyperplasia / etiology. Female. Humans. Incidence. Medical Records. Middle Aged. Retrospective Studies. Romania / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16285581.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


83. Yemelyanova A, Vang R, Seidman JD, Gravitt PE, Ronnett BM: Endocervical adenocarcinomas with prominent endometrial or endomyometrial involvement simulating primary endometrial carcinomas: utility of HPV DNA detection and immunohistochemical expression of p16 and hormone receptors to confirm the cervical origin of the corpus tumor. Am J Surg Pathol; 2009 Jun;33(6):914-24
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endocervical adenocarcinomas with prominent endometrial or endomyometrial involvement simulating primary endometrial carcinomas: utility of HPV DNA detection and immunohistochemical expression of p16 and hormone receptors to confirm the cervical origin of the corpus tumor.
  • Determining the primary site of a uterine adenocarcinoma can be problematic in hysterectomy specimens due to the overlapping morphology of endocervical adenocarcinomas and endometrial carcinomas, particularly when both the corpus (usually lower uterine segment) and endocervix are involved and precursor lesions are lacking or difficult to distinguish from intramucosal spread of carcinoma from one site to the other.
  • Both preferential extension of endocervical adenocarcinomas into the endometrium (rather than deep cervical stroma) and myometrial invasion derived from the endometrial component are rarely encountered; to our knowledge, these unusual patterns of spread have not been detailed in prior reports.
  • Clinicopathologic features of 10 endocervical adenocarcinomas (9 pure, 1 adenosquamous) with prominent endometrial or endomyometrial involvement were evaluated.
  • Six cases had limited amounts of tumor in the cervix proper, with depths of invasion no greater than 5 mm in 4 and only adenocarcinoma in situ in 2.
  • Four cases had cervical stromal invasion of more than 5 mm but all of these had greater amounts of horizontal extension into endometrium or endomyometrium.
  • Four tumors extended into endometrium only and 6 had myoinvasion associated with the endometrial component.
  • Five tumors were originally diagnosed as primary endometrial carcinoma with either cervical extension or concurrent endocervical adenocarcinoma in situ.
  • These ancillary techniques are useful for clarifying the origin of uterine adenocarcinomas when morphologic features and tumor location are equivocal.
  • These cases illustrate that dominant uterine corpus involvement (endometrial or endomyometrial) by primary endocervical adenocarcinoma can lead to misclassification as primary endometrial adenocarcinoma with cervical extension (Fédération Internationale de Gynécologie et d'Obstétrique stage II), especially when endometrial extension of endocervical adenocarcinoma simulates complex atypical hyperplasia.
  • A subset of misclassified endocervical adenocarcinomas may account for some HPV-positive uterine carcinomas reported as primary endometrial carcinomas.
  • [MeSH-major] Adenocarcinoma / diagnosis. Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis. DNA, Viral / analysis. Endometrial Neoplasms / diagnosis. Receptors, Steroid / biosynthesis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Diagnosis, Differential. Endometrium / metabolism. Endometrium / pathology. Endometrium / virology. Female. Humans. Immunohistochemistry. In Situ Hybridization. Middle Aged. Papillomaviridae. Papillomavirus Infections / diagnosis. Papillomavirus Infections / metabolism. Papillomavirus Infections / pathology. Receptors, Estrogen / biosynthesis. Receptors, Progesterone / biosynthesis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19295407.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Viral; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Receptors, Steroid
  •  go-up   go-down


84. Roshani L, Mallon P, Sjostrand E, Wedekind D, Szpirer J, Szpirer C, Hedrich HJ, Klinga-Levan K: Genetic analysis of susceptibility to endometrial adenocarcinoma in the BDII rat model. Cancer Genet Cytogenet; 2005 Apr 15;158(2):137-41
SciCrunch. RGD: Data: Animal Model .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic analysis of susceptibility to endometrial adenocarcinoma in the BDII rat model.
  • Females of the BDII inbred rat strain are genetically predisposed to endometrial cancer; more than 90% of virgin BDII females will develop endometrial adenocarcinoma (EAC) during their life span.
  • Furthermore, it seems clear from the interstrain crosses not only that the onset of tumors depends on the presence of susceptibility alleles from the EAC-prone BDII strain, but also that tumor development is affected by the contribution of a genetic component derived from the nonsusceptible strains.
  • [MeSH-major] Adenocarcinoma / genetics. Disease Models, Animal. Endometrial Neoplasms / genetics. Genetic Predisposition to Disease

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15796960.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Genetic Markers
  •  go-up   go-down


85. Hidaka T, Nakamura T, Shima T, Yuki H, Saito S: Paclitaxel/carboplatin versus cyclophosphamide/adriamycin/cisplatin as postoperative adjuvant chemotherapy for advanced endometrial adenocarcinoma. J Obstet Gynaecol Res; 2006 Jun;32(3):330-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel/carboplatin versus cyclophosphamide/adriamycin/cisplatin as postoperative adjuvant chemotherapy for advanced endometrial adenocarcinoma.
  • AIM: There is no standard chemotherapy regimen for patients with advanced endometrial adenocarcinoma.
  • METHODS: Twenty-eight patients who underwent surgery and had histologically confirmed advanced endometrial adenocarcinoma, International Federation of Gynecology and Obstetrics stage III/IV, received combination chemotherapy.
  • National Cancer Institute Common Toxicity Criteria grade 3-4 thrombocytopenia and gastrointestinal toxicities occurred significantly less frequently in the paclitaxel/carboplatin group (0% and 16.7%) than in the CAP group (31.3% and 68.8%) (P = 0.0389 and P = 0.0062).
  • CONCLUSIONS: We conclude that paclitaxel/carboplatin is a promising regimen which could be substituted for CAP, with major activity and a highly acceptable toxicity profile for the treatment of advanced endometrial adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endometrial Neoplasms / drug therapy

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16764625.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


86. Corrado G, Baiocco E, Carosi M, Vizza E: Progression of conservatively treated endometrial complex atypical hyperplasia in a young woman: a case report. Fertil Steril; 2008 Nov;90(5):2006.e5-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progression of conservatively treated endometrial complex atypical hyperplasia in a young woman: a case report.
  • OBJECTIVE: To describe a case of progression of endometrial complex atypical hyperplasia (CAH) to extrauterine endometrioid adenocarcinoma in a patient who had requested fertility-sparing management.
  • SETTING: Division of Gynecologic Oncology, National Cancer Institute "Regina Elena," Rome, Italy.
  • PATIENT(S): A nulliparous 36-year-old woman with endometrial CAH who decided on a conservative approach.
  • INTERVENTION(S): Conservative hysteroscopic resection of the lesion, the surrounding endometrium, and underlying myometrium plus hormone therapy regimen of megestrol acetate (160 mg) daily for 6 months.
  • RESULT(S): Eighteen months after fertility-sparing management, a laparoscopic operation revealed grade 2 endometrium adenocarcinoma with superficial myometrial invasion and a microscopic metastasis of the left ovary and Douglas peritoneum.
  • CONCLUSION(S): Conservative therapy is feasible in carefully selected young women with endometrial CAH.
  • However, close follow-up is required because of possible progression to endometrial cancer.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Hyperplasia / therapy. Endometrial Neoplasms / pathology. Hysteroscopy. Megestrol Acetate / therapeutic use. Precancerous Conditions / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18692828.001).
  • [ISSN] 1556-5653
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] TJ2M0FR8ES / Megestrol Acetate
  •  go-up   go-down


87. Cirpan T, Terek MC, Mgoyi L, Zekioglu O, Iscan O, Ozsaran A: Immunohistochemical evaluation of PTEN protein in patients with endometrial intraepithelial neoplasia compared to endometrial adenocarcinoma and proliferative phase endometrium. Eur J Gynaecol Oncol; 2006;27(4):389-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical evaluation of PTEN protein in patients with endometrial intraepithelial neoplasia compared to endometrial adenocarcinoma and proliferative phase endometrium.
  • OBJECTIVE: The aim of this study was to reclassify endometrial hyperplasia cases and examine PTEN protein immunoreactivity compared to cases with endometrial adenocarcinoma and proliferative endometrium.
  • DESIGN: Endometrial samples from 37 women with endometrial hyperplasia with atypia were reclassified as endometrial intraepithelial neoplasia (EIN).
  • Eighteen were complex and 19 were simple endometrial hyperplasia.
  • Twenty-our cases of EIN, ten endometrial adenocarcinoma cases and ten proliferative phase endometrium sections were immunostained for PTEN expression.
  • RESULTS: Twenty-four of 37 (64%) women with endometrial hyperplasia were reclassified as EIN.
  • There were no difference in PTEN immunoreactivity between EIN, endometrial adenocarcinoma and endometrial proliferation (p = 0.342).
  • PTEN immunoreactivity was partially lost in seven and present in three of the patients with endometrial adenocarcinoma.
  • CONCLUSION: EIN classification may provide a better and more objective assessment of endometrial hyperplasia cases.
  • PTEN expression showed no differences among the cases of EIN, endometrial carcinoma and proliferative phase endometrium.
  • [MeSH-major] Adenocarcinoma / metabolism. Cell Proliferation. Endometrial Hyperplasia / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. PTEN Phosphohydrolase / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17009632.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


88. Oshiro H, Miyagi Y, Kawaguchi Y, Rino Y, Arai H, Asai-Sato M, Nakayama H, Yamanaka S, Inayama Y, Fukushima N: Endometrial adenocarcinoma without myometrial invasion metastasizing to the pancreas and masquerading as primary pancreatic neoplasm. Pathol Int; 2008 Jul;58(7):456-61
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial adenocarcinoma without myometrial invasion metastasizing to the pancreas and masquerading as primary pancreatic neoplasm.
  • Reported herein is a case of endometrial adenocarcinoma without myometrial invasion that metastasized to the pancreas in a 69-year-old Japanese woman who had a history of hysterectomy.
  • Excised in distal pancreatectomy, the tumor was diagnosed as a pancreatic primary, an invasive papillary adenocarcinoma at first, but both the endometrial tumor and the pancreatic tumor demonstrated similar morphology and immunohistochemistry.
  • Furthermore, the identical nucleotide mutation of TP53 gene was observed from both the endometrial and pancreatic tumors.
  • The pancreatic tumor was therefore confirmed to be a metastasis from the primary endometrial adenocarcinoma.
  • Metastasis to the pancreas from endometrial carcinoma is extremely rare but must be considered even if the previous cancer was treated at an early stage.
  • Histopathological comparison study and genetic analysis are important for the correct diagnosis of metastasis.
  • [MeSH-major] Adenocarcinoma / secondary. Endometrial Neoplasms / pathology. Pancreatic Neoplasms / secondary
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / pathology. Aged. Base Sequence. Diagnosis, Differential. Female. Genes, p53. Humans. Hysterectomy. Immunohistochemistry. Molecular Sequence Data. Mutation

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18577117.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


89. Jaffe JS, Chambers JT: Endometrial adenocarcinoma presenting in a premenopausal patient with tuberous sclerosis. J Intellect Disabil Res; 2005 Jun;49(Pt 6):463-5
MedlinePlus Health Information. consumer health - Tuberous Sclerosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial adenocarcinoma presenting in a premenopausal patient with tuberous sclerosis.
  • BACKGROUND: Endometrial adenocarcinoma is very uncommon in women under 40 years of age.
  • She was subsequently found to have a deeply invasive endometrial adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Endometrial Neoplasms / diagnosis. Premenopause. Tuberous Sclerosis / genetics

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15882396.001).
  • [ISSN] 0964-2633
  • [Journal-full-title] Journal of intellectual disability research : JIDR
  • [ISO-abbreviation] J Intellect Disabil Res
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


90. Kimmich T, Brüning A, Käufl SD, Makovitzky J, Kuhn C, Jeschke U, Friese K, Mylonas I: Inhibin/activin-betaC and -betaE subunits in the Ishikawa human endometrial adenocarcinoma cell line. Arch Gynecol Obstet; 2010 Aug;282(2):185-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibin/activin-betaC and -betaE subunits in the Ishikawa human endometrial adenocarcinoma cell line.
  • However, only limited data on the expression of these novel inhibin subunits in normal human endometrial tissue and endometrial adenocarcinoma cell lines exist.
  • MATERIALS AND METHODS: Samples of proliferative and secretory human endometrium were obtained from five premenopausal, non-pregnant patients undergoing gynecological surgery for benign diseases.
  • Normal endometrial tissue and Ishikawa endometrial adenocarcinoma cell lines were analyzed by immunohistochemistry, immunofluorescence and RT-PCR.
  • RESULTS: Expression of the inhibin betaC and betaE subunits could be demonstrated at the protein level by means of immunohistochemical evaluation and at the transcriptional level by establishing a betaC- and betaE-specific RT-PCR analysis in normal human endometrial tissue and the parental Ishikawa cell line.
  • Interestingly, in a highly de-differentiated subclone of the Ishikawa cell line lacking estrogen receptor expression, the expression of the inhibin-betaC subunit appeared strongly reduced.
  • DISCUSSION: Here, we show for the first time that the novel inhibin/activin-betaC and -betaE subunits are expressed in normal human endometrium and the estrogen receptor positive human endometrial carcinoma cell line Ishikawa using RT-PCR and immunohistochemical detection methods.
  • Interestingly, the Ishikawa minus cell line (lacking estrogen receptor expression) demonstrated no to minimal expression of the betaC subunit as observed with immunofluorescence and RT-PCR, suggesting a possible hormone- dependency of this subunit in human endometrial cancer cells.
  • Moreover, because the Ishikawa cell line minus is thought to be a more malignant endometrial cell line than its estrogen receptor positive counterpart, inhibin-betaC subunit might be substantially involved in the pathogenesis and malignant transformation in human endometrium.
  • [MeSH-major] Adenocarcinoma / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Inhibin-beta Subunits / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20012305.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / INHBC protein, human; 0 / INHBE protein, human; 0 / Receptors, Estrogen; 93443-12-0 / Inhibin-beta Subunits
  •  go-up   go-down


91. Mazur MT: Endometrial hyperplasia/adenocarcinoma. a conventional approach. Ann Diagn Pathol; 2005 Jun;9(3):174-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial hyperplasia/adenocarcinoma. a conventional approach.
  • Hyperplasia of the endometrium is a process characterized by an irregular, noninvasive proliferation of glands with a variable amount of stroma.
  • Precise classification of endometrial hyperplasia in biopsy material is important in order to identify those hyperplasias that are likely to be precursors of endometrial adenocarcinoma.
  • A wide variety of other endometrial changes, ranging from artifacts, metaplasias and polyps to well-differentiated adenocarcinoma must be considered in the differential diagnosis.
  • Well-differentiated adenocarcinoma is diagnosed when one of 3 essential criteria is found in biopsy specimens:.
  • Using the WHO classification allows segregation of endometrial hyperplasia into clinically meaningful categories.
  • Strict morphologic criteria also enable separation of hyperplasia from well-differentiated adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Hyperplasia / pathology. Endometrial Neoplasms / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Biopsy. Endometrium / pathology. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15944963.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 46
  •  go-up   go-down


92. Giaginis CT, Zarros AC, Papaefthymiou MA, Papadopouli AE, Sfiniadakis IK, Theocharis SE: Coxsackievirus and adenovirus receptor expression in human endometrial adenocarcinoma: possible clinical implications. World J Surg Oncol; 2008;6:59
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coxsackievirus and adenovirus receptor expression in human endometrial adenocarcinoma: possible clinical implications.
  • The aim of the present study was to evaluate the clinical significance of CAR expression in endometrial adenocarcinoma.
  • CAR expression was assessed immunohistochemically in tumoral samples of 41 endometrial adenocarcinoma patients and was statistically analyzed in relation to various clinicopathological parameters, tumor proliferative capacity and patient survival.
  • CAR positivity was noted in 23 out of 41 (56%) endometrial adenocarcinoma cases, while high CAR expression in 8 out of 23 (35%) positive ones.
  • These data reveal, for the first time, the expression of CAR in clinical material obtained from patients with endometrial adenocarcinoma in relation to important clinicopathological parameters for their management.
  • As CAR appears to modulate the proliferation and characteristics of cancer cells, its expression could be considered of possible clinical importance for future (gene) therapy applications.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoviridae Infections / metabolism. Coxsackievirus Infections / metabolism. Endometrial Neoplasms / metabolism. Receptors, Virus / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1998 Dec 15;58(24):5738-48 [9865732.001]
  • [Cites] Int J Cancer. 2007 Oct 15;121(8):1690-6 [17546646.001]
  • [Cites] J Virol. 1999 Mar;73(3):2559-62 [9971843.001]
  • [Cites] Curr Opin Oncol. 2007 Sep;19(5):479-85 [17762575.001]
  • [Cites] Gynecol Oncol. 2007 Oct;107(1):143-53 [17692907.001]
  • [Cites] Dig Dis Sci. 2008 Jun;53(6):1728-34 [17932753.001]
  • [Cites] Cancer Gene Ther. 1999 Mar-Apr;6(2):113-38 [10195879.001]
  • [Cites] Int J Cancer. 2005 Feb 20;113(5):738-45 [15499626.001]
  • [Cites] Adv Drug Deliv Rev. 2005 Apr 25;57(6):869-82 [15820557.001]
  • [Cites] Clin Exp Med. 2005 Oct;5(3):122-8 [16284735.001]
  • [Cites] J Neurooncol. 2006 May;78(1):1-6 [16314939.001]
  • [Cites] Hum Genet. 1999 Oct;105(4):354-9 [10543405.001]
  • [Cites] Brain Res Mol Brain Res. 2000 Apr 14;77(1):19-28 [10814828.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5031-6 [11016624.001]
  • [Cites] Gene Ther. 2000 Nov;7(22):1954-68 [11127584.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2953-60 [11306473.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6592-600 [11522659.001]
  • [Cites] J Urol. 2002 Apr;167(4):1836-43 [11912444.001]
  • [Cites] Gynecol Oncol. 2002 May;85(2):260-5 [11972385.001]
  • [Cites] Biochim Biophys Acta. 2002 May 3;1575(1-3):1-14 [12020813.001]
  • [Cites] Urology. 2002 Sep;60(3):531-6 [12350512.001]
  • [Cites] Int J Cancer. 2003 Mar 1;103(6):723-9 [12516090.001]
  • [Cites] Br J Cancer. 2003 May 6;88(9):1411-6 [12778071.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4992-9 [14581374.001]
  • [Cites] Clin Cancer Res. 2004 Jun 1;10(11):3831-8 [15173092.001]
  • [Cites] J Virol. 1994 Sep;68(9):5925-32 [7520097.001]
  • [Cites] Science. 1997 Feb 28;275(5304):1320-3 [9036860.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13159-64 [9789058.001]
  • [Cites] J Virol. 1998 Dec;72(12):9706-13 [9811704.001]
  • [Cites] Hum Gene Ther. 1998 Nov 1;9(16):2363-73 [9829535.001]
  • [Cites] Cancer Gene Ther. 2006 Aug;13(8):792-7 [16628228.001]
  • [Cites] Cancer Immunol Immunother. 2006 Nov;55(11):1412-9 [16612598.001]
  • [Cites] J Mol Histol. 2006 May;37(3-4):153-60 [17031523.001]
  • [Cites] Pathology. 2007 Feb;39(1):72-87 [17365824.001]
  • [Cites] Int J Cancer. 2007 Jun 15;120(12):2568-75 [17278108.001]
  • [Cites] Neuropathology. 2007 Jun;27(3):233-6 [17645237.001]
  • [Cites] Fertil Steril. 2007 Aug;88(2):462-71 [17343855.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):325-30 [9927041.001]
  • (PMID = 18558015.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CLMP protein, human; 0 / Coxsackie and Adenovirus Receptor-Like Membrane Protein; 0 / Receptors, Virus; 0 / adenovirus receptor
  • [Other-IDs] NLM/ PMC2440381
  •  go-up   go-down


93. Srikantia N, B R, A G R, Kalyan SN: Endometrioid endometrial adenocarcinoma in a premenopausal woman with multiple organ metastases. Indian J Med Paediatr Oncol; 2009 Apr;30(2):80-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid endometrial adenocarcinoma in a premenopausal woman with multiple organ metastases.
  • Endometrial adenocarcinoma is the third common malignancy of the female genital tract occurring most often in the postmenopausal age group.
  • We present an unusual case of endometrial adenocarcinoma in a premenopausal woman with simultaneous metastases in brain, liver, skin and skeletal system, within one month of completion of treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1997 Jun;65(3):530-3 [9190989.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jul;21(3):281-4 [12068176.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):168-73 [15093913.001]
  • [Cites] Gynecol Oncol. 2004 May;93(2):524-8 [15099973.001]
  • [Cites] Expert Rev Anticancer Ther. 2004 Aug;4(4):679-89 [15270671.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):333-9 [15297170.001]
  • [Cites] Gan To Kagaku Ryoho. 2008 Sep;35(9):1488-94 [18799902.001]
  • [Cites] Anticancer Res. 2009 May;29(5):1715-20 [19443392.001]
  • (PMID = 20596308.001).
  • [ISSN] 0975-2129
  • [Journal-full-title] Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology
  • [ISO-abbreviation] Indian J Med Paediatr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2885881
  • [Keywords] NOTNLM ; Adjuvant chemotherapy / endometrial carcinoma / multiple organ metastases
  •  go-up   go-down


94. Kazmierczak W, Skalba P, Dabkowska-Huc A, Samojedny A: Expression of aromatase and 5-alpha-reductase genes in endometrial adenocarcinoma. Pathol Res Pract; 2006;202(11):789-91
Hazardous Substances Data Bank. TESTOSTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of aromatase and 5-alpha-reductase genes in endometrial adenocarcinoma.
  • The aim of this study was to investigate the expression of genes coding aromatase and 5-alpha-reductase type 1 and type 2 in endometrial adenocarcinoma, with parallel analysis of testosterone concentrations in serum isolated from blood of basilic and ovarian vein.
  • We concluded that in tissues of endometrial adenocarcinoma, there is expression of aromatase and 5-alpha-reductase type 1 and 2 genes, and that the expression of aromatase and 5-alpha-reductase genes in tissues of endometrial adenocarcinoma is not controlled by testosterone.
  • [MeSH-major] 3-Oxo-5-alpha-Steroid 4-Dehydrogenase / genetics. Adenocarcinoma / blood. Adenocarcinoma / genetics. Aromatase / genetics. Endometrial Neoplasms / blood. Endometrial Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17010533.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Isoenzymes; 0 / RNA, Messenger; 3XMK78S47O / Testosterone; EC 1.14.14.1 / Aromatase; EC 1.3.99.5 / 3-Oxo-5-alpha-Steroid 4-Dehydrogenase
  •  go-up   go-down


95. Thrall M, Kjeldahl K, Savik K, Gulbahce HE, Pambuccian SE: Rate of endometrial adenocarcinoma in women screened before and after implementation of the Bethesda 2001 reporting system. Acta Cytol; 2008 Jan-Feb;52(1):1-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rate of endometrial adenocarcinoma in women screened before and after implementation of the Bethesda 2001 reporting system.
  • OBJECTIVE: To assess the impact of the recommendation of the 2001 Bethesda System to report all benign-appearing endometrial cells seen in women aged > or = 40 years on the frequency with which endometrial carcinomas are potentially detected as a consequence of Pap test reports that mention endometrial cells.
  • STUDY DESIGN: We identified all women diagnosed with endometrial adenocarcinoma who also had a Pap test during the preceding 6 months.
  • RESULTS: Benign endometrial cells were reported for 589 women in the 3 years before Bethesda 2001 and for 3,810 women in the 3 following years.
  • The number of endometrial malignancies found on follow-up in these women decreased from 8 in the 3 years before Bethesda 2001 to only 4 subsequently.
  • The frequency of reporting atypical or malignant glandular cells, as well as the likelihood of finding endometrial malignancy on follow-up, did not significantly change.
  • CONCLUSION: Despite a 6.5-fold rise in the frequency of reporting benign endometrial cells after Bethesda 2001, the frequency of subsequent diagnosis of endometrial malignancies did not in-crease.
  • [MeSH-major] Adenocarcinoma / epidemiology. Endometrial Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18323269.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Chung TK, Cheung TH, Huen NY, Wong KW, Lo KW, Yim SF, Siu NS, Wong YM, Tsang PT, Pang MW, Yu MY, To KF, Mok SC, Wang VW, Li C, Cheung AY, Doran G, Birrer MJ, Smith DI, Wong YF: Dysregulated microRNAs and their predicted targets associated with endometrioid endometrial adenocarcinoma in Hong Kong women. Int J Cancer; 2009 Mar 15;124(6):1358-65
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dysregulated microRNAs and their predicted targets associated with endometrioid endometrial adenocarcinoma in Hong Kong women.
  • The objective of this study, a parallel study to global gene expression profiling, was to identify dysregulated microRNAs (miRNAs) associated with endometrioid endometrial adenocarcinoma (EEC), examine their correlation with clinico-pathological characteristics and identify predicted target genes of the dysregulated miRNAs.
  • The expression of a sub-group of miRNAs was significantly correlated with clinico-pathological characteristics including stage, myometrial invasion, recurrence and lymph node involvement.
  • After transfection of a miR-205 inhibitor, the expression of miR-205 in endometrial cancer cell line RL95-2 cells decreased whereas its predicted target gene, JPH4, showed increased protein expression.
  • JPH4 seems to be a real miR-205 target in vitro and in vivo, and a candidate tumor suppressor gene in EEC.
  • This work provides a framework on which further research into novel diagnosis and treatment of EEC can be focused.
  • [MeSH-major] Carcinoma, Endometrioid / genetics. Endometrial Neoplasms / genetics. Gene Expression Regulation, Neoplastic. MicroRNAs / genetics
  • [MeSH-minor] Adult. Aged. Cell Line, Tumor. Endometrium / cytology. Endometrium / pathology. Female. Hong Kong. Humans. Middle Aged. Postmenopause. RNA, Neoplasm / genetics. RNA, Neoplasm / isolation & purification. Reference Values

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19065659.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / RNA, Neoplasm
  •  go-up   go-down


97. Donoghue JF, Lederman FL, Susil BJ, Rogers PA: Lymphangiogenesis of normal endometrium and endometrial adenocarcinoma. Hum Reprod; 2007 Jun;22(6):1705-13
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphangiogenesis of normal endometrium and endometrial adenocarcinoma.
  • BACKGROUND: Information about lymphatics and lymphangiogenesis in the human endometrium is limited.
  • We investigated the distribution of endometrial lymphatic vessels during the normal menstrual cycle and in association with endometrial adenocarcinoma and investigated the expression of lymphangiogenic growth factors, vascular endothelial growth factor (VEGF)-C, VEGF-D and VEGF receptor-3 (VEGF-R3).
  • METHODS AND RESULTS: Full thickness uterine samples (n = 23 proliferative; n = 23 secretory) and endometrial adenocarcinoma samples (n = 7 grade I; n = 10 grade III) were collected for the study and analysed by immunohistochemistry and western blotting.
  • Lymphatic vessels of endometrial adenocarcinomas were located intra-tumoural and peri-tumoural with significant increases in the peri-tumoural lymphatic vessels compared with normal basalis (P = 0.02).
  • Interestingly, high-grade adenocarcinoma vessels containing tumour emboli demonstrated a mixed blood/lymphatic endothelial cell phenotype.
  • VEGF-C and VEGF-D were immunolocalized in glandular epithelium and some stromal cells with the staining intensity of this localization increasing in endometrial adenocarcinoma.
  • Protein analysis identified VEGF-C (58, 41, 31 and 21 kD) and VEGF-D (56, 41, 31 and 21 kD) and VEGF-R3 (148 and 65 kD) peptides in normal endometrium, with significant increases in several of these peptides for VEGF-C and VEGF-D and no changes in protein expression for VEGF-R3 in endometrial adenocarcinoma.
  • CONCLUSION: Endometrial lymphatics are significantly reduced in the functionalis, and increases in endometrial adenocarcinoma peri-tumoural lymphatics are associated with increases in VEGF-C and VEGF-D peptides.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Endometrium / anatomy & histology. Lymphangiogenesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17347164.001).
  • [ISSN] 0268-1161
  • [Journal-full-title] Human reproduction (Oxford, England)
  • [ISO-abbreviation] Hum. Reprod.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Vascular Endothelial Growth Factor C; 0 / Vascular Endothelial Growth Factor D; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-3
  •  go-up   go-down


98. Yoshida M, Watanabe G, Suzuki T, Inoue K, Takahashi M, Maekawa A, Taya K, Nishikawa A: Long-term treatment with bromocriptine inhibits endometrial adenocarcinoma development in rats. J Reprod Dev; 2009 Apr;55(2):105-9
Hazardous Substances Data Bank. MENOTROPINS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term treatment with bromocriptine inhibits endometrial adenocarcinoma development in rats.
  • The effects of long-term blockade of prolactin (PRL) action by bromocriptine (BRC) treatment on uterine carcinogenesis and on related ovarian physiology were investigated using a rat uterine cancer model.
  • Ten-week-old cycling female Donryu rats, a high yield strain for uterine corpus tumors (endometrial adenocarcinomas), were treated with N-ethyl-N'-nitro-N-nitrosoguanidine (ENNG), as a tumor initiator, and injected with 1 mg/kg body weight BRC subcutaneously 4 times per week until 14.5 months of age to block the proestrus PRL surge.
  • The study was terminated at 15 months of age, and the results showed that long-term BRC treatment significantly inhibited endometrial adenocarcinoma development in terms of both incidence (34.6% to 13.0% with significant difference at 5%) and multiplicity (0.35 to 0.18 with significant difference at 5%), which indicates the number of adenocarcinomas per animals.
  • [MeSH-major] Adenocarcinoma / prevention & control. Bromocriptine / pharmacology. Endometrial Neoplasms / prevention & control

  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. PROGESTERONE .
  • Hazardous Substances Data Bank. N-METHYL-N'-NITRO-N-NITROSOGUANIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106489.001).
  • [ISSN] 0916-8818
  • [Journal-full-title] The Journal of reproduction and development
  • [ISO-abbreviation] J. Reprod. Dev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Hormone Antagonists; 12H3O2UGSF / Methylnitronitrosoguanidine; 3A64E3G5ZO / Bromocriptine; 4245-77-6 / ENNG; 4G7DS2Q64Y / Progesterone; 4TI98Z838E / Estradiol; 57285-09-3 / Inhibins; 9002-62-4 / Prolactin; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


99. Cerezo L, Cárdenes H, Michael H: Molecular alterations in the pathogenesis of endometrial adenocarcinoma. Therapeutic implications. Clin Transl Oncol; 2006 Apr;8(4):231-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular alterations in the pathogenesis of endometrial adenocarcinoma. Therapeutic implications.
  • Molecular genetic evidence indicates that endometrial carcinoma likely develops as the result of a multistep process of oncogene activation and tumor suppressor gene inactivation.
  • These molecular alterations appear to be specific for Type I (endometrioid) and Type II (non endometrioid) cancers.
  • Type I cancers are characterized by mutation of PTEN, KRAS2, defects in DNA mismatch repair, as evidenced by the microsatellite instability phenotype, and a near diploid karyotype.
  • The clinical value of many of these molecular markers is now being tested and it may help to refine diagnosis and establish an accurate prognosis.
  • Transtuzumab against Her-2/neu and bevacizumab against VEGF overexpressing carcinomas are among the promising novel treatments.
  • [MeSH-major] Adenocarcinoma / etiology. Cell Transformation, Neoplastic / genetics. Endometrial Neoplasms / etiology. Neoplasms, Hormone-Dependent / etiology

  • Hazardous Substances Data Bank. PROGESTERONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16648098.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Estrogens; 0 / Neoplasm Proteins; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 4G7DS2Q64Y / Progesterone; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Number-of-references] 85
  •  go-up   go-down


100. Chebib I, Chu P, Duggan MA, DiFrancesco LM: Primary signet-ring cell adenocarcinoma of the endometrium: case report and review of the literature. Int J Gynecol Pathol; 2010 May;29(3):269-72
MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary signet-ring cell adenocarcinoma of the endometrium: case report and review of the literature.
  • Endometrial adenocarcinoma presenting with deep venous thrombosis is an exceptional event more typical of extra-mullerian primary tumors.
  • In addition, primary endometrial adenocarcinoma with signet-ring cell features has been reported only once.
  • This study describes a case of primary endometrial carcinoma with prominent signet-ring cell features that presented in an unusual manner: with bilateral deep vein thromboses and splenic metastases.
  • [MeSH-major] Carcinoma, Signet Ring Cell / pathology. Endometrial Neoplasms / pathology. Splenic Neoplasms / secondary. Venous Thrombosis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20407328.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement